FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Front Med (Lausanne) / Exploring Animal Models That Resemble Idiopathic Pulmonary F...
Frontiers in medicine2017; 4; 118; doi: 10.3389/fmed.2017.00118

Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis.

Abstract: Large multicenter clinical trials have led to two recently approved drugs for patients with idiopathic pulmonary fibrosis (IPF); yet, both of these therapies only slow disease progression and do not provide a definitive cure. Traditionally, preclinical trials have utilized mouse models of bleomycin (BLM)-induced pulmonary fibrosis-though several limitations prevent direct translation to human IPF. Spontaneous pulmonary fibrosis occurs in other animal species, including dogs, horses, donkeys, and cats. While the fibrotic lungs of these animals share many characteristics with lungs of patients with IPF, current veterinary classifications of fibrotic lung disease are not entirely equivalent. Additional studies that profile these examples of spontaneous fibroses in animals for similarities to human IPF should prove useful for both human and animal investigators. In the meantime, studies of BLM-induced fibrosis in aged male mice remain the most clinically relevant model for preclinical study for human IPF. Addressing issues such as time course of treatment, animal size and characteristics, clinically irrelevant treatment endpoints, and reproducibility of therapeutic outcomes will improve the current status of preclinical studies. Elucidating the mechanisms responsible for the development of fibrosis and disrepair associated with aging through a collaborative approach between researchers will promote the development of models that more accurately represent the realm of interstitial lung diseases in humans.
Get Full Text
Publication Date: 2017-07-28 PubMed ID: 28804709PubMed Central: PMC5532376DOI: 10.3389/fmed.2017.00118Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study explores different animal models that resemble Idiopathic Pulmonary Fibrosis (IPF), a disorder characterized by progressive scarring of the lungs. The research investigates limitations in existing models such as the Bleomycin-induced fibrosis in mice, and highlights the potential exploration of spontaneous fibrosis in animals like dogs, horses, donkeys, and cats for better understanding of the human disease.

Context and Objective

  • The research acknowledges that while there are two recently approved drugs for IPF, they only slow down the progression of the disease instead of providing a cure. Therefore, it highlights the need for more comprehensive animal studies that mimic the human condition to develop more effective therapeutic solutions.

Focused Animal Models

  • One predominant model is based on mice using the agent Bleomycin (blm)- which induces pulmonary fibrosis. Yet this model has limitations including lack of direct translation to the human version of IPF and issues of reproducibility and relevant endpoints for human treatment.
  • The paper suggests exploring examples of spontaneous fibrosis in other species such as or dogs, horses, donkeys, and cats, as many characteristics of their fibrotic lungs share similarities with human IPF. However, it points out the veterinary classification of lung diseases in these animals isn’t completely equivalent.

Advancement and Recommendations

  • The authors propose more studies to profile spontaneous fibrosis in these animals and compare them to human IPF, benefitting both human and animal health research spheres.
  • Furthermore, they argue that despite its limitations the blm-induced fibrosis in aged male mice is currently the most clinically relevant model for preclinical study of human IPF.
  • There’s also a call for resolving issues such as the time course of treatment, the size and features of the animals used, and clinically irrelevant treatment endpoints, to enhance the utility of preclinical studies.
  • Finally, the authors underline that mutual collaborations between researchers in understanding the mechanisms leading to fibrosis and the lack of repair due to aging can help develop models that provide a closer match to the range of interstitial lung diseases in humans.

Cite This Article

APA
(2017). Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis. Front Med (Lausanne), 4, 118. https://doi.org/10.3389/fmed.2017.00118

Publication

Frontiers in medicine
ISSN: 2296-858X
NlmUniqueID: 101648047
Country: Switzerland
Language: English
Volume: 4
Pages: 118
PII: 118

Researcher Affiliations

References

This article includes 117 references
  1. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schünemann HJ. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.. Am J Respir Crit Care Med 2015 Jul 15;192(2):e3-19.
    doi: 10.1164/rccm.201506-1063STpubmed: 26177183google scholar: lookup
  2. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.. Am J Respir Crit Care Med 2013 Sep 15;188(6):733-48.
    doi: 10.1164/rccm.201308-1483STpmc: PMC5803655pubmed: 24032382google scholar: lookup
  3. Ryu JH, Moua T, Daniels CE, Hartman TE, Yi ES, Utz JP, Limper AH. Idiopathic pulmonary fibrosis: evolving concepts.. Mayo Clin Proc 2014 Aug;89(8):1130-42.
    doi: 10.1016/j.mayocp.2014.03.016pubmed: 24867394google scholar: lookup
  4. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, Brown KK, Chapman HA, Collard HR, Cosgrove GP, Deterding R, Doyle R, Flaherty KR, Garcia CK, Hagood JS, Henke CA, Herzog E, Hogaboam CM, Horowitz JC, King TE Jr, Loyd JE, Lawson WE, Marsh CB, Noble PW, Noth I, Sheppard D, Olsson J, Ortiz LA, O'Riordan TG, Oury TD, Raghu G, Roman J, Sime PJ, Sisson TH, Tschumperlin D, Violette SM, Weaver TE, Wells RG, White ES, Kaminski N, Martinez FJ, Wynn TA, Thannickal VJ, Eu JP. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.. Am J Respir Crit Care Med 2014 Jan 15;189(2):214-22.
    doi: 10.1164/rccm.201306-1141WSpmc: PMC3983890pubmed: 24160862google scholar: lookup
  5. Ahluwalia N, Shea BS, Tager AM. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.. Am J Respir Crit Care Med 2014 Oct 15;190(8):867-78.
    doi: 10.1164/rccm.201403-0509PPpmc: PMC4299574pubmed: 25090037google scholar: lookup
  6. Chilosi M, Carloni A, Rossi A, Poletti V. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema.. Transl Res 2013 Sep;162(3):156-73.
    doi: 10.1016/j.trsl.2013.06.004pubmed: 23831269google scholar: lookup
  7. Tzouvelekis A, Kaminski N. Epigenetics in idiopathic pulmonary fibrosis.. Biochem Cell Biol 2015 Apr;93(2):159-70.
    doi: 10.1139/bcb-2014-0126pubmed: 25659821google scholar: lookup
  8. Jones MG, Fletcher S, Richeldi L. Idiopathic pulmonary fibrosis: recent trials and current drug therapy.. Respiration 2013;86(5):353-63.
    doi: 10.1159/000356958pubmed: 24296982google scholar: lookup
  9. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, Collard HR. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.. Lancet Respir Med 2014 Jul;2(7):566-72.
    doi: 10.1016/S2213-2600(14)70101-8pubmed: 24875841google scholar: lookup
  10. Spagnolo P, Tzouvelekis A, Maher TM. Personalized medicine in idiopathic pulmonary fibrosis: facts and promises.. Curr Opin Pulm Med 2015 Sep;21(5):470-8.
    doi: 10.1097/MCP.0000000000000187pubmed: 26132817google scholar: lookup
  11. Tzouvelekis A, Bonella F, Spagnolo P. Update on therapeutic management of idiopathic pulmonary fibrosis.. Ther Clin Risk Manag 2015;11:359-70.
    doi: 10.2147/TCRM.S69716pmc: PMC4354471pubmed: 25767391google scholar: lookup
  12. Tzouvelekis A, Herazo-Maya J, Sakamoto K, Bouros D. Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis.. Curr Top Med Chem 2016;16(14):1587-98.
    doi: 10.2174/1568026616666150930120959pubmed: 26420365google scholar: lookup
  13. Tzouvelekis A, Tzilas V, Papiris S, Aidinis V, Bouros D. Diagnostic and prognostic challenges in Idiopathic Pulmonary Fibrosis: A patient's "Q and A" approach.. Pulm Pharmacol Ther 2017 Feb;42:21-24.
    doi: 10.1016/j.pupt.2016.12.002pubmed: 27979760google scholar: lookup
  14. Tzouvelekis A, Yu G, Lino Cardenas CL, Herazo-Maya JD, Wang R, Woolard T, Zhang Y, Sakamoto K, Lee H, Yi JS, DeIuliis G, Xylourgidis N, Ahangari F, Lee PJ, Aidinis V, Herzog EL, Homer R, Bennett AM, Kaminski N. SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis.. Am J Respir Crit Care Med 2017 Feb 15;195(4):500-514.
    doi: 10.1164/rccm.201602-0329OCpmc: PMC5378419pubmed: 27736153google scholar: lookup
  15. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.. N Engl J Med 2014 May 29;370(22):2083-92.
    doi: 10.1056/NEJMoa1402582pubmed: 24836312google scholar: lookup
  16. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.. N Engl J Med 2014 May 29;370(22):2071-82.
    doi: 10.1056/NEJMoa1402584pubmed: 24836310google scholar: lookup
  17. Bouros D, Tzouvelekis A. Idiopathic pulmonary fibrosis: on the move.. Lancet Respir Med 2014 Jan;2(1):17-9.
    doi: 10.1016/S2213-2600(13)70240-6pubmed: 24461889google scholar: lookup
  18. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?. Int J Biochem Cell Biol 2008;40(3):362-82.
    doi: 10.1016/j.biocel.2007.08.011pmc: PMC2323681pubmed: 17936056google scholar: lookup
  19. Mouratis MA, Aidinis V. Modeling pulmonary fibrosis with bleomycin.. Curr Opin Pulm Med 2011 Sep;17(5):355-61.
    doi: 10.1097/MCP.0b013e328349ac2bpubmed: 21832918google scholar: lookup
  20. B Moore B, Lawson WE, Oury TD, Sisson TH, Raghavendran K, Hogaboam CM. Animal models of fibrotic lung disease.. Am J Respir Cell Mol Biol 2013 Aug;49(2):167-79.
    doi: 10.1165/rcmb.2013-0094TRpmc: PMC3824038pubmed: 23526222google scholar: lookup
  21. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis.. Am J Physiol Lung Cell Mol Physiol 2008 Feb;294(2):L152-60.
    doi: 10.1152/ajplung.00313.2007pubmed: 17993587google scholar: lookup
  22. Organ L, Bacci B, Koumoundouros E, Barcham G, Kimpton W, Nowell CJ, Samuel C, Snibson K. A novel segmental challenge model for bleomycin-induced pulmonary fibrosis in sheep.. Exp Lung Res 2015 Apr;41(3):115-34.
    doi: 10.3109/01902148.2014.985806pubmed: 25531791google scholar: lookup
  23. Jenkins RG, Moore BB, Chambers RC, Eickelberg O, Königshoff M, Kolb M, Laurent GJ, Nanthakumar CB, Olman MA, Pardo A, Selman M, Sheppard D, Sime PJ, Tager AM, Tatler AL, Thannickal VJ, White ES. An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis.. Am J Respir Cell Mol Biol 2017 May;56(5):667-679.
    doi: 10.1165/rcmb.2017-0096STpmc: PMC5800895pubmed: 28459387google scholar: lookup
  24. Degryse AL, Tanjore H, Xu XC, Polosukhin VV, Jones BR, McMahon FB, Gleaves LA, Blackwell TS, Lawson WE. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis.. Am J Physiol Lung Cell Mol Physiol 2010 Oct;299(4):L442-52.
    doi: 10.1152/ajplung.00026.2010pmc: PMC2957416pubmed: 20562227google scholar: lookup
  25. Cai Y, Zhu L, Zhang F, Niu G, Lee S, Kimura S, Chen X. Noninvasive monitoring of pulmonary fibrosis by targeting matrix metalloproteinases (MMPs).. Mol Pharm 2013 Jun 3;10(6):2237-47.
    doi: 10.1021/mp300613xpmc: PMC3672268pubmed: 23607644google scholar: lookup
  26. Sueblinvong V, Neujahr DC, Mills ST, Roser-Page S, Ritzenthaler JD, Guidot D, Rojas M, Roman J. Predisposition for disrepair in the aged lung.. Am J Med Sci 2012 Jul;344(1):41-51.
    doi: 10.1097/MAJ.0b013e318234c132pmc: PMC3395069pubmed: 22173045google scholar: lookup
  27. Naik PK, Moore BB. Viral infection and aging as cofactors for the development of pulmonary fibrosis.. Expert Rev Respir Med 2010 Dec;4(6):759-71.
    doi: 10.1586/ers.10.73pmc: PMC3028433pubmed: 21128751google scholar: lookup
  28. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, Burns L, Renteria L, Woods J, Chen L, Allard J, Ravindran P, Bitter H, Liang Z, Hogaboam CM, Kitson C, Budd DC, Fine JS, Bauer CM, Stevenson CS. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease.. PLoS One 2013;8(4):e59348.
    doi: 10.1371/journal.pone.0059348pmc: PMC3614979pubmed: 23565148google scholar: lookup
  29. Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis.. Int J Exp Pathol 2002 Jun;83(3):111-9.
    doi: 10.1046/j.1365-2613.2002.00220.xpmc: PMC2517673pubmed: 12383190google scholar: lookup
  30. Stefanov AN, Fox J, Depault F, Haston CK. Positional cloning reveals strain-dependent expression of Trim16 to alter susceptibility to bleomycin-induced pulmonary fibrosis in mice.. PLoS Genet 2013;9(1):e1003203.
    doi: 10.1371/journal.pgen.1003203pmc: PMC3547790pubmed: 23341783google scholar: lookup
  31. Hoyt DG, Lazo JS. Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice.. J Pharmacol Exp Ther 1988 Aug;246(2):765-71.
    pubmed: 2457084
  32. Aguilar S, Scotton CJ, McNulty K, Nye E, Stamp G, Laurent G, Bonnet D, Janes SM. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis.. PLoS One 2009 Nov 24;4(11):e8013.
    doi: 10.1371/journal.pone.0008013pmc: PMC2779453pubmed: 19956603google scholar: lookup
  33. Redente EF, Jacobsen KM, Solomon JJ, Lara AR, Faubel S, Keith RC, Henson PM, Downey GP, Riches DW. Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis.. Am J Physiol Lung Cell Mol Physiol 2011 Oct;301(4):L510-8.
    doi: 10.1152/ajplung.00122.2011pmc: PMC3191751pubmed: 21743030google scholar: lookup
  34. Chung MP, Monick MM, Hamzeh NY, Butler NS, Powers LS, Hunninghake GW. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis.. Am J Respir Cell Mol Biol 2003 Sep;29(3 Pt 1):375-80.
    doi: 10.1165/rcmb.2003-0029OCpubmed: 12676806google scholar: lookup
  35. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, Phinney DG. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects.. Proc Natl Acad Sci U S A 2003 Jul 8;100(14):8407-11.
    doi: 10.1073/pnas.1432929100pmc: PMC166242pubmed: 12815096google scholar: lookup
  36. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, Brigham KL. Bone marrow-derived mesenchymal stem cells in repair of the injured lung.. Am J Respir Cell Mol Biol 2005 Aug;33(2):145-52.
    doi: 10.1165/rcmb.2004-0330OCpmc: PMC2715309pubmed: 15891110google scholar: lookup
  37. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury.. Proc Natl Acad Sci U S A 2007 Jun 26;104(26):11002-7.
    doi: 10.1073/pnas.0704421104pmc: PMC1891813pubmed: 17569781google scholar: lookup
  38. Foskett AM, Bazhanov N, Ti X, Tiblow A, Bartosh TJ, Prockop DJ. Phase-directed therapy: TSG-6 targeted to early inflammation improves bleomycin-injured lungs.. Am J Physiol Lung Cell Mol Physiol 2014 Jan;306(2):L120-31.
    doi: 10.1152/ajplung.00240.2013pmc: PMC3920207pubmed: 24242012google scholar: lookup
  39. Hecker L, Logsdon NJ, Kurundkar D, Kurundkar A, Bernard K, Hock T, Meldrum E, Sanders YY, Thannickal VJ. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance.. Sci Transl Med 2014 Apr 9;6(231):231ra47.
    doi: 10.1126/scitranslmed.3008182pmc: PMC4545252pubmed: 24718857google scholar: lookup
  40. Srour N, Thébaud B. Mesenchymal Stromal Cells in Animal Bleomycin Pulmonary Fibrosis Models: A Systematic Review.. Stem Cells Transl Med 2015 Dec;4(12):1500-10.
    doi: 10.5966/sctm.2015-0121pmc: PMC4675510pubmed: 26494779google scholar: lookup
  41. Cross J, Stenton GR, Harwig C, Szabo C, Genovese T, Di Paola R, Esposito E, Cuzzocrea S, Mackenzie LF. AQX-1125, small molecule SHIP1 activator inhibits bleomycin-induced pulmonary fibrosis.. Br J Pharmacol 2017 Sep;174(18):3045-3057.
    doi: 10.1111/bph.13934pmc: PMC5573425pubmed: 28658529google scholar: lookup
  42. Tanaka KI, Niino T, Ishihara T, Takafuji A, Takayama T, Kanda Y, Sugizaki T, Tamura F, Kurotsu S, Kawahara M, Mizushima T. Protective and therapeutic effect of felodipine against bleomycin-induced pulmonary fibrosis in mice.. Sci Rep 2017 Jun 13;7(1):3439.
    doi: 10.1038/s41598-017-03676-ypmc: PMC5469778pubmed: 28611390google scholar: lookup
  43. Lee SH, Lee EJ, Lee SY, Kim JH, Shim JJ, Shin C, In KH, Kang KH, Uhm CS, Kim HK, Yang KS, Park S, Kim HS, Kim YM, Yoo TJ. The effect of adipose stem cell therapy on pulmonary fibrosis induced by repetitive intratracheal bleomycin in mice.. Exp Lung Res 2014 Apr;40(3):117-25.
    doi: 10.3109/01902148.2014.881930pubmed: 24624895google scholar: lookup
  44. Moodley Y, Vaghjiani V, Chan J, Baltic S, Ryan M, Tchongue J, Samuel CS, Murthi P, Parolini O, Manuelpillai U. Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study.. PLoS One 2013;8(8):e69299.
    doi: 10.1371/journal.pone.0069299pmc: PMC3731305pubmed: 23936322google scholar: lookup
  45. Davis GS, Leslie KO, Hemenway DR. Silicosis in mice: effects of dose, time, and genetic strain.. J Environ Pathol Toxicol Oncol 1998;17(2):81-97.
    pubmed: 9546745
  46. Davis GS, Pfeiffer LM, Hemenway DR. Interferon-gamma production by specific lung lymphocyte phenotypes in silicosis in mice.. Am J Respir Cell Mol Biol 2000 Apr;22(4):491-501.
    doi: 10.1165/ajrcmb.22.4.3599pubmed: 10745030google scholar: lookup
  47. Antonini JM, Hemenway DR, Davis GS. Quantitative image analysis of lung connective tissue in murine silicosis.. Exp Lung Res 2000 Mar;26(2):71-88.
    doi: 10.1080/019021400269880pubmed: 10742923google scholar: lookup
  48. Davis GS, Pfeiffer LM, Hemenway DR. Expansion of interferon-gamma-producing lung lymphocytes in mouse silicosis.. Am J Respir Cell Mol Biol 1999 Apr;20(4):813-24.
    doi: 10.1165/ajrcmb.20.4.3407pubmed: 10101015google scholar: lookup
  49. Davis GS, Pfeiffer LM, Hemenway DR. Persistent overexpression of interleukin-1beta and tumor necrosis factor-alpha in murine silicosis.. J Environ Pathol Toxicol Oncol 1998;17(2):99-114.
    pubmed: 9546746
  50. Lakatos HF, Burgess HA, Thatcher TH, Redonnet MR, Hernady E, Williams JP, Sime PJ. Oropharyngeal aspiration of a silica suspension produces a superior model of silicosis in the mouse when compared to intratracheal instillation.. Exp Lung Res 2006 May;32(5):181-99.
    doi: 10.1080/01902140600817465pubmed: 16908446google scholar: lookup
  51. Barbarin V, Arras M, Misson P, Delos M, McGarry B, Phan SH, Lison D, Huaux F. Characterization of the effect of interleukin-10 on silica-induced lung fibrosis in mice.. Am J Respir Cell Mol Biol 2004 Jul;31(1):78-85.
    doi: 10.1165/rcmb.2003-0299OCpubmed: 14975940google scholar: lookup
  52. Barbarin V, Xing Z, Delos M, Lison D, Huaux F. Pulmonary overexpression of IL-10 augments lung fibrosis and Th2 responses induced by silica particles.. Am J Physiol Lung Cell Mol Physiol 2005 May;288(5):L841-8.
    doi: 10.1152/ajplung.00329.2004pubmed: 15608148google scholar: lookup
  53. Davis GS, Holmes CE, Pfeiffer LM, Hemenway DR. Lymphocytes, lymphokines, and silicosis.. J Environ Pathol Toxicol Oncol 2001;20 Suppl 1:53-65.
    doi: 10.1615/JEnvironPatholToxicolOncol.v20.iSuppl.1.50pubmed: 11570674google scholar: lookup
  54. Misson P, van den Brûle S, Barbarin V, Lison D, Huaux F. Markers of macrophage differentiation in experimental silicosis.. J Leukoc Biol 2004 Nov;76(5):926-32.
    doi: 10.1189/jlb.0104019pubmed: 15292275google scholar: lookup
  55. Baur X, Woitowitz HJ, Budnik LT, Egilman D, Oliver C, Frank A, Soskolne CL, Landrigan PJ, Lemen RA. Asbestos, asbestosis, and cancer: The Helsinki criteria for diagnosis and attribution. Critical need for revision of the 2014 update.. Am J Ind Med 2017 May;60(5):411-421.
    doi: 10.1002/ajim.22709pubmed: 28409857google scholar: lookup
  56. Roggli V, Gibbs AR, Attanoos R, Churg A, Popper H, Corrin B, Franks T, Galateau-Salle F, Galvin J, Hasleton P, Honma K. Pathology of Asbestosis: An Update of the Diagnostic Criteria Response to a Critique.. Arch Pathol Lab Med 2016 Sep;140(9):950-2.
    doi: 10.5858/arpa.2015-0503-SApubmed: 27575267google scholar: lookup
  57. Kim SJ, Cheresh P, Jablonski RP, Williams DB, Kamp DW. The Role of Mitochondrial DNA in Mediating Alveolar Epithelial Cell Apoptosis and Pulmonary Fibrosis.. Int J Mol Sci 2015 Sep 7;16(9):21486-519.
    doi: 10.3390/ijms160921486pmc: PMC4613264pubmed: 26370974google scholar: lookup
  58. Cyphert JM, Padilla-Carlin DJ, Schladweiler MC, Shannahan JH, Nyska A, Kodavanti UP, Gavett SH. Long-term response of rats to single intratracheal exposure of Libby amphibole or amosite.. J Toxicol Environ Health A 2012;75(3):183-200.
    doi: 10.1080/15287394.2012.641203pubmed: 22251266google scholar: lookup
  59. Rasmussen DL, Pfau JC. Asbestos activates CH12.LX B-lymphocytes via macrophage signaling.. J Immunotoxicol 2012 Apr-Jun;9(2):129-40.
    doi: 10.3109/1547691X.2011.631953pmc: PMC3655430pubmed: 22133189google scholar: lookup
  60. Padilla-Carlin DJ, Schladweiler MC, Shannahan JH, Kodavanti UP, Nyska A, Burgoon LD, Gavett SH. Pulmonary inflammatory and fibrotic responses in Fischer 344 rats after intratracheal instillation exposure to Libby amphibole.. J Toxicol Environ Health A 2011;74(17):1111-32.
    doi: 10.1080/15287394.2011.586940pubmed: 21797767google scholar: lookup
  61. Li J, Poovey HG, Rodriguez JF, Brody A, Hoyle GW. Effect of platelet-derived growth factor on the development and persistence of asbestos-induced fibroproliferative lung disease.. J Environ Pathol Toxicol Oncol 2004;23(4):253-66.
    doi: 10.1615/JEnvPathToxOncol.v23.i4.20pubmed: 15511213google scholar: lookup
  62. Selman M, Buendía-Roldán I, Pardo A. Aging and Pulmonary Fibrosis.. Rev Invest Clin 2016 Mar-Apr;68(2):75-83.
    pubmed: 27103043
  63. Meiners S, Eickelberg O, Königshoff M. Hallmarks of the ageing lung.. Eur Respir J 2015 Mar;45(3):807-27.
    doi: 10.1183/09031936.00186914pubmed: 25657021google scholar: lookup
  64. Thannickal VJ, Murthy M, Balch WE, Chandel NS, Meiners S, Eickelberg O, Selman M, Pardo A, White ES, Levy BD, Busse PJ, Tuder RM, Antony VB, Sznajder JI, Budinger GR. Blue journal conference. Aging and susceptibility to lung disease.. Am J Respir Crit Care Med 2015 Feb 1;191(3):261-9.
    doi: 10.1164/rccm.201410-1876PPpmc: PMC4351581pubmed: 25590812google scholar: lookup
  65. Englert JM, Hanford LE, Kaminski N, Tobolewski JM, Tan RJ, Fattman CL, Ramsgaard L, Richards TJ, Loutaev I, Nawroth PP, Kasper M, Bierhaus A, Oury TD. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis.. Am J Pathol 2008 Mar;172(3):583-91.
    doi: 10.2353/ajpath.2008.070569pmc: PMC2258251pubmed: 18245812google scholar: lookup
  66. Samuel CS, Zhao C, Bond CP, Hewitson TD, Amento EP, Summers RJ. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis.. Kidney Int 2004 Jun;65(6):2054-64.
    doi: 10.1111/j.1523-1755.2004.00628.xpubmed: 15149318google scholar: lookup
  67. Samuel CS, Zhao C, Bathgate RA, Bond CP, Burton MD, Parry LJ, Summers RJ, Tang ML, Amento EP, Tregear GW. Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis.. FASEB J 2003 Jan;17(1):121-3.
    doi: 10.1096/fj.02-0449fjepubmed: 12424226google scholar: lookup
  68. Naik PN, Horowitz JC, Moore TA, Wilke CA, Toews GB, Moore BB. Pulmonary fibrosis induced by γ-herpesvirus in aged mice is associated with increased fibroblast responsiveness to transforming growth factor-β.. J Gerontol A Biol Sci Med Sci 2012 Jun;67(7):714-25.
    doi: 10.1093/gerona/glr211pmc: PMC3391066pubmed: 22193547google scholar: lookup
  69. Torres-González E, Bueno M, Tanaka A, Krug LT, Cheng DS, Polosukhin VV, Sorescu D, Lawson WE, Blackwell TS, Rojas M, Mora AL. Role of endoplasmic reticulum stress in age-related susceptibility to lung fibrosis.. Am J Respir Cell Mol Biol 2012 Jun;46(6):748-56.
    doi: 10.1165/rcmb.2011-0224OCpmc: PMC3380287pubmed: 22227563google scholar: lookup
  70. Egan JJ, Adamali HI, Lok SS, Stewart JP, Woodcock AA. Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: an open pilot study.. Pulm Med 2011;2011:240805.
    doi: 10.1155/2011/240805pmc: PMC3109335pubmed: 21660226google scholar: lookup
  71. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung.. J Clin Invest 1997 Aug 15;100(4):768-76.
    doi: 10.1172/JCI119590pmc: PMC508247pubmed: 9259574google scholar: lookup
  72. Lee CG, Kang HR, Homer RJ, Chupp G, Elias JA. Transgenic modeling of transforming growth factor-beta(1): role of apoptosis in fibrosis and alveolar remodeling.. Proc Am Thorac Soc 2006 Jul;3(5):418-23.
    doi: 10.1513/pats.200602-017AWpmc: PMC2658706pubmed: 16799085google scholar: lookup
  73. Vicencio AG, Lee CG, Cho SJ, Eickelberg O, Chuu Y, Haddad GG, Elias JA. Conditional overexpression of bioactive transforming growth factor-beta1 in neonatal mouse lung: a new model for bronchopulmonary dysplasia?. Am J Respir Cell Mol Biol 2004 Dec;31(6):650-6.
    doi: 10.1165/rcmb.2004-0092OCpubmed: 15333328google scholar: lookup
  74. Lee CG, Cho SJ, Kang MJ, Chapoval SP, Lee PJ, Noble PW, Yehualaeshet T, Lu B, Flavell RA, Milbrandt J, Homer RJ, Elias JA. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis.. J Exp Med 2004 Aug 2;200(3):377-89.
    doi: 10.1084/jem.20040104pmc: PMC2211975pubmed: 15289506google scholar: lookup
  75. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis.. J Clin Invest 2001 Jun;107(12):1529-36.
    doi: 10.1172/JCI12568pmc: PMC200196pubmed: 11413160google scholar: lookup
  76. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL, Gauldie J. Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts.. Am J Pathol 1998 Sep;153(3):825-32.
    doi: 10.1016/S0002-9440(10)65624-6pmc: PMC1853002pubmed: 9736031google scholar: lookup
  77. Xing Z, Tremblay GM, Sime PJ, Gauldie J. Overexpression of granulocyte-macrophage colony-stimulating factor induces pulmonary granulation tissue formation and fibrosis by induction of transforming growth factor-beta 1 and myofibroblast accumulation.. Am J Pathol 1997 Jan;150(1):59-66.
    pmc: PMC1858539pubmed: 9006322
  78. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1).. J Exp Med 2001 Sep 17;194(6):809-21.
    doi: 10.1084/jem.194.6.809pmc: PMC2195954pubmed: 11560996google scholar: lookup
  79. Roberts SN, Howie SE, Wallace WA, Brown DM, Lamb D, Ramage EA, Donaldson K. A novel model for human interstitial lung disease: hapten-driven lung fibrosis in rodents.. J Pathol 1995 Jul;176(3):309-18.
    doi: 10.1002/path.1711760313pubmed: 7674093google scholar: lookup
  80. Christensen PJ, Goodman RE, Pastoriza L, Moore B, Toews GB. Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell-dependent.. Am J Pathol 1999 Nov;155(5):1773-9.
    doi: 10.1016/S0002-9440(10)65493-4pmc: PMC1866962pubmed: 10550334google scholar: lookup
  81. Moore BB, Paine R 3rd, Christensen PJ, Moore TA, Sitterding S, Ngan R, Wilke CA, Kuziel WA, Toews GB. Protection from pulmonary fibrosis in the absence of CCR2 signaling.. J Immunol 2001 Oct 15;167(8):4368-77.
    doi: 10.4049/jimmunol.167.8.4368pubmed: 11591761google scholar: lookup
  82. Karvonen RL, Fernandez-Madrid F, Maughan RL, Palmer KC, Fernandez-Madrid I. An animal model of pulmonary radiation fibrosis with biochemical, physiologic, immunologic, and morphologic observations.. Radiat Res 1987 Jul;111(1):68-80.
    doi: 10.2307/3577022pubmed: 3602356google scholar: lookup
  83. Paun A, Haston CK. Genomic and genome-wide association of susceptibility to radiation-induced fibrotic lung disease in mice.. Radiother Oncol 2012 Dec;105(3):350-7.
    doi: 10.1016/j.radonc.2012.08.004pubmed: 22954495google scholar: lookup
  84. Haston CK. Mouse genetic approaches applied to the normal tissue radiation response.. Front Oncol 2012;2:94.
    doi: 10.3389/fonc.2012.00094pmc: PMC3413016pubmed: 22891164google scholar: lookup
  85. Paun A, Fox J, Balloy V, Chignard M, Qureshi ST, Haston CK. Combined Tlr2 and Tlr4 deficiency increases radiation-induced pulmonary fibrosis in mice.. Int J Radiat Oncol Biol Phys 2010 Jul 15;77(4):1198-205.
    doi: 10.1016/j.ijrobp.2009.12.065pubmed: 20610040google scholar: lookup
  86. Haston CK, Travis EL. Murine susceptibility to radiation-induced pulmonary fibrosis is influenced by a genetic factor implicated in susceptibility to bleomycin-induced pulmonary fibrosis.. Cancer Res 1997 Dec 1;57(23):5286-91.
    pubmed: 9393751
  87. Haston CK, Amos CI, King TM, Travis EL. Inheritance of susceptibility to bleomycin-induced pulmonary fibrosis in the mouse.. Cancer Res 1996 Jun 1;56(11):2596-601.
    pubmed: 8653703
  88. Naikawadi RP, Disayabutr S, Mallavia B, Donne ML, Green G, La JL, Rock JR, Looney MR, Wolters PJ. Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis.. JCI Insight 2016 Sep 8;1(14):e86704.
    doi: 10.1172/jci.insight.86704pmc: PMC5033906pubmed: 27699234google scholar: lookup
  89. Povedano JM, Martinez P, Flores JM, Mulero F, Blasco MA. Mice with Pulmonary Fibrosis Driven by Telomere Dysfunction.. Cell Rep 2015 Jul 14;12(2):286-99.
    doi: 10.1016/j.celrep.2015.06.028pubmed: 26146081google scholar: lookup
  90. Armanios M. Telomerase and idiopathic pulmonary fibrosis.. Mutat Res 2012 Feb 1;730(1-2):52-8.
    doi: 10.1016/j.mrfmmm.2011.10.013pmc: PMC3292861pubmed: 22079513google scholar: lookup
  91. Driscoll B, Buckley S, Bui KC, Anderson KD, Warburton D. Telomerase in alveolar epithelial development and repair.. Am J Physiol Lung Cell Mol Physiol 2000 Dec;279(6):L1191-8.
    pubmed: 11076809doi: 10.1152/ajplung.2000.279.6.L1191google scholar: lookup
  92. Kim JK, Lim Y, Kim KA, Seo MS, Kim JD, Lee KH, Park CY. Activation of telomerase by silica in rat lung.. Toxicol Lett 2000 Jan 5;111(3):263-70.
    doi: 10.1016/S0378-4274(99)00195-2pubmed: 10643871google scholar: lookup
  93. Liu T, Chung MJ, Ullenbruch M, Yu H, Jin H, Hu B, Choi YY, Ishikawa F, Phan SH. Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice.. J Clin Invest 2007 Dec;117(12):3800-9.
    doi: 10.1172/JCI32369pmc: PMC2075478pubmed: 18008008google scholar: lookup
  94. Degryse AL, Xu XC, Newman JL, Mitchell DB, Tanjore H, Polosukhin VV, Jones BR, McMahon FB, Gleaves LA, Phillips JA 3rd, Cogan JD, Blackwell TS, Lawson WE. Telomerase deficiency does not alter bleomycin-induced fibrosis in mice.. Exp Lung Res 2012 Apr;38(3):124-34.
    doi: 10.3109/01902148.2012.658148pmc: PMC4046256pubmed: 22394286google scholar: lookup
  95. Nogee LM, Dunbar AE 3rd, Wert S, Askin F, Hamvas A, Whitsett JA. Mutations in the surfactant protein C gene associated with interstitial lung disease.. Chest 2002 Mar;121(3 Suppl):20S-21S.
    doi: 10.1378/chest.121.3_suppl.20Spubmed: 11893657google scholar: lookup
  96. Nogee LM, Dunbar AE 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease.. N Engl J Med 2001 Feb 22;344(8):573-9.
    doi: 10.1056/NEJM200102223440805pubmed: 11207353google scholar: lookup
  97. Glasser SW, Detmer EA, Ikegami M, Na CL, Stahlman MT, Whitsett JA. Pneumonitis and emphysema in sp-C gene targeted mice.. J Biol Chem 2003 Apr 18;278(16):14291-8.
    doi: 10.1074/jbc.M210909200pubmed: 12519727google scholar: lookup
  98. Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, Flaherty KR, Martinez FJ, Hogaboam CM. Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice.. Am J Pathol 2007 Apr;170(4):1152-64.
    doi: 10.2353/ajpath.2007.060649pmc: PMC1829450pubmed: 17392156google scholar: lookup
  99. Trujillo G, Meneghin A, Flaherty KR, Sholl LM, Myers JL, Kazerooni EA, Gross BH, Oak SR, Coelho AL, Evanoff H, Day E, Toews GB, Joshi AD, Schaller MA, Waters B, Jarai G, Westwick J, Kunkel SL, Martinez FJ, Hogaboam CM. TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis.. Sci Transl Med 2010 Nov 10;2(57):57ra82.
    doi: 10.1126/scitranslmed.3001510pmc: PMC3235647pubmed: 21068441google scholar: lookup
  100. Fujii H, Luo ZJ, Kim HJ, Newbigging S, Gassas A, Keating A, Egeler RM. Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation.. PLoS One 2015;10(7):e0133216.
    doi: 10.1371/journal.pone.0133216pmc: PMC4503770pubmed: 26176698google scholar: lookup
  101. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research.. Nat Rev Immunol 2007 Feb;7(2):118-30.
    doi: 10.1038/nri2017pubmed: 17259968google scholar: lookup
  102. Roman J, Brown KK, Olson A, Corcoran BM, Williams KJ. An official American thoracic society workshop report: comparative pathobiology of fibrosing lung disorders in humans and domestic animals.. Ann Am Thorac Soc 2013 Dec;10(6):S224-9.
    doi: 10.1513/AnnalsATS.201309-321STpubmed: 24364785google scholar: lookup
  103. Williams KJ, Maes R, Del Piero F, Lim A, Wise A, Bolin DC, Caswell J, Jackson C, Robinson NE, Derksen F, Scott MA, Uhal BD, Li X, Youssef SA, Bolin SR. Equine multinodular pulmonary fibrosis: a newly recognized herpesvirus-associated fibrotic lung disease.. Vet Pathol 2007 Nov;44(6):849-62.
    doi: 10.1354/vp.44-6-849pubmed: 18039898google scholar: lookup
  104. Norris AJ, Naydan DK, Wilson DW. Interstitial lung disease in West Highland White Terriers.. Vet Pathol 2005 Jan;42(1):35-41.
    doi: 10.1354/vp.42-1-35pubmed: 15657270google scholar: lookup
  105. Miele A, Dhaliwal K, Du Toit N, Murchison JT, Dhaliwal C, Brooks H, Smith SH, Hirani N, Schwarz T, Haslett C, Wallace WA, McGorum BC. Chronic pleuropulmonary fibrosis and elastosis of aged donkeys: similarities to human pleuroparenchymal fibroelastosis.. Chest 2014 Jun;145(6):1325-1332.
    doi: 10.1378/chest.13-1306pubmed: 24889435google scholar: lookup
  106. Wong DM, Belgrave RL, Williams KJ, Del Piero F, Alcott CJ, Bolin SR, Marr CM, Nolen-Walston R, Myers RK, Wilkins PA. Multinodular pulmonary fibrosis in five horses.. J Am Vet Med Assoc 2008 Mar 15;232(6):898-905.
    doi: 10.2460/javma.232.6.898pubmed: 18341449google scholar: lookup
  107. Mercer PF, Abbott-Banner K, Adcock IM, Knowles RG. Translational models of lung disease.. Clin Sci (Lond) 2015 Feb;128(4):235-56.
    doi: 10.1042/CS20140373pubmed: 25328010google scholar: lookup
  108. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.. Am J Respir Crit Care Med 2011 Mar 15;183(6):788-824.
    doi: 10.1164/rccm.2009-040GLpmc: PMC5450933pubmed: 21471066google scholar: lookup
  109. Syrjä P, Heikkilä HP, Lilja-Maula L, Krafft E, Clercx C, Day MJ, Rönty M, Myllärniemi M, Rajamäki MM. The histopathology of idiopathic pulmonary fibrosis in West Highland white terriers shares features of both non-specific interstitial pneumonia and usual interstitial pneumonia in man.. J Comp Pathol 2013 Aug-Oct;149(2-3):303-13.
    doi: 10.1016/j.jcpa.2013.03.006pubmed: 23664319google scholar: lookup
  110. Thierry F, Handel I, Hammond G, King LG, Corcoran BM, Schwarz T. Further characterization of computed tomographic and clinical features for staging and prognosis of idiopathic pulmonary fibrosis in West Highland white terriers.. Vet Radiol Ultrasound 2017 Jul;58(4):381-388.
    doi: 10.1111/vru.12491pubmed: 28335088google scholar: lookup
  111. Williams KJ, Robinson NE, Lim A, Brandenberger C, Maes R, Behan A, Bolin SR. Experimental induction of pulmonary fibrosis in horses with the gammaherpesvirus equine herpesvirus 5.. PLoS One 2013;8(10):e77754.
    doi: 10.1371/journal.pone.0077754pmc: PMC3795644pubmed: 24147074google scholar: lookup
  112. Williams K, Malarkey D, Cohn L, Patrick D, Dye J, Toews G. Identification of spontaneous feline idiopathic pulmonary fibrosis: morphology and ultrastructural evidence for a type II pneumocyte defect.. Chest 2004 Jun;125(6):2278-88.
    doi: 10.1378/chest.125.6.2278pubmed: 15189952google scholar: lookup
  113. Back H, Ullman K, Leijon M, Söderlund R, Penell J, Ståhl K, Pringle J, Valarcher JF. Genetic variation and dynamics of infections of equid herpesvirus 5 in individual horses.. J Gen Virol 2016 Jan;97(1):169-178.
    doi: 10.1099/jgv.0.000332pubmed: 26518010google scholar: lookup
  114. Antoniu SA, Kolb MR. Update on models of pulmonary fibrosis therapy for preclinical drug research.. Expert Opin Drug Discov 2009 Sep;4(9):939-46.
    doi: 10.1517/17460440903186100pubmed: 23480541google scholar: lookup
  115. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models.. Eur Respir Rev 2011 Jun;20(120):85-97.
    doi: 10.1183/09059180.00001111pubmed: 21632796google scholar: lookup
  116. Huang J, Beyer C, Palumbo-Zerr K, Zhang Y, Ramming A, Distler A, Gelse K, Distler O, Schett G, Wollin L, Distler JH. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.. Ann Rheum Dis 2016 May;75(5):883-90.
    doi: 10.1136/annrheumdis-2014-207109pubmed: 25858641google scholar: lookup
  117. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.. J Pharmacol Exp Ther 2014 May;349(2):209-20.
    doi: 10.1124/jpet.113.208223pubmed: 24556663google scholar: lookup

Citations

This article has been cited 168 times.
  1. Blutt SE, Coarfa C, Neu J, Pammi M. Multiomic Investigations into Lung Health and Disease. Microorganisms 2023 Aug 19;11(8).
    doi: 10.3390/microorganisms11082116pubmed: 37630676google scholar: lookup
  2. Castiglione F, Çakır OÖ, Schifano N, Corona G, Reisman Y, Bettocchi C, Cellek S, Ilg MM. European Society of Sexual Medicine consensus statement on the use of animal models for studying Peyronie's disease. Sex Med 2023 Aug;11(4):qfad046.
    doi: 10.1093/sexmed/qfad046pubmed: 37547872google scholar: lookup
  3. Kurniawan SV, Louisa M, Zaini J, Surini S, Soetikno V, Wuyung PE, Uli RCT. Acute exacerbation of idiopathic pulmonary fibrosis model in the rats using bleomycin and lipopolysaccharides. J Adv Vet Anim Res 2023 Jun;10(2):196-204.
    doi: 10.5455/javar.2023.j669pubmed: 37534065google scholar: lookup
  4. Volpe MC, Ciucci G, Zandomenego G, Vuerich R, Ring NAR, Vodret S, Salton F, Marchesan P, Braga L, Marcuzzo T, Bussani R, Colliva A, Piazza S, Confalonieri M, Zacchigna S. Flt1 produced by lung endothelial cells impairs ATII cell transdifferentiation and repair in pulmonary fibrosis. Cell Death Dis 2023 Jul 15;14(7):437.
    doi: 10.1038/s41419-023-05962-2pubmed: 37454154google scholar: lookup
  5. Simon KS, Coelho LC, Veloso PHH Jr, Melo-Silva CA, Morais JAV, Longo JPF, Figueiredo F, Viana L, Silva Pereira I, Amado VM, Mortari MR, Bocca AL. Innovative Pre-Clinical Data Using Peptides to Intervene in the Evolution of Pulmonary Fibrosis. Int J Mol Sci 2023 Jul 4;24(13).
    doi: 10.3390/ijms241311049pubmed: 37446227google scholar: lookup
  6. Mai TH, Han LW, Hsu JC, Kamath N, Pan L. Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective. Ther Adv Respir Dis 2023 Jan-Dec;17:17534666231181537.
    doi: 10.1177/17534666231181537pubmed: 37392011google scholar: lookup
  7. Basta MD, Petruk S, Summer R, Rosenbloom J, Wermuth PJ, Macarak E, Levin AV, Mazo A, Walker JL. Changes in nascent chromatin structure regulate activation of the pro-fibrotic transcriptome and myofibroblast emergence in organ fibrosis. iScience 2023 May 19;26(5):106570.
    doi: 10.1016/j.isci.2023.106570pubmed: 37250334google scholar: lookup
  8. Valenzi E, Bahudhanapati H, Tan J, Tabib T, Sullivan DI, Nouraie M, Sembrat J, Fan L, Chen K, Liu S, Rojas M, Lafargue A, Felsher DW, Tran PT, Kass DJ, Lafyatis R. Single-nucleus chromatin accessibility identifies a critical role for TWIST1 in idiopathic pulmonary fibrosis myofibroblast activity. Eur Respir J 2023 Jul;62(1).
    doi: 10.1183/13993003.00474-2022pubmed: 37142338google scholar: lookup
  9. Chen Y, Hao X, Li M, Tian Z, Cheng M. UGRP1-modulated MARCO(+) alveolar macrophages contribute to age-related lung fibrosis. Immun Ageing 2023 Mar 18;20(1):14.
    doi: 10.1186/s12979-023-00338-8pubmed: 36934284google scholar: lookup
  10. Han S, Lu Q, Liu X. Advances in cellular senescence in idiopathic pulmonary fibrosis (Review). Exp Ther Med 2023 Apr;25(4):145.
    doi: 10.3892/etm.2023.11844pubmed: 36911379google scholar: lookup
  11. Gu S, Liang J, Zhang J, Liu Z, Miao Y, Wei Y, Li S, Gu J, Cui Y, Xiao T, Li X, Yang C. Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway. Molecules 2023 Feb 27;28(5).
    doi: 10.3390/molecules28052195pubmed: 36903446google scholar: lookup
  12. Kadam AH, Schnitzer JE. Characterization of acute lung injury in the bleomycin rat model. Physiol Rep 2023 Mar;11(5):e15618.
    doi: 10.14814/phy2.15618pubmed: 36898724google scholar: lookup
  13. Yang X, Huang XJ, Chen Z, Xu AL, Zhou H, Bi XL, Yan PY, Xie Y. A novel quantification method of lung fibrosis based on Micro-CT images developed with the optimized pulmonary fibrosis mice model induced by bleomycin. Heliyon 2023 Mar;9(3):e13598.
    doi: 10.1016/j.heliyon.2023.e13598pubmed: 36895392google scholar: lookup
  14. Fakhouri F, Joseph M, Ballinger M, Shukla V, Weimar D, Novak C, Ghadiali S, Kolipaka A. Magnetic Resonance Elastography (MRE) of Bleomycin-Induced Pulmonary Fibrosis in an Animal Model. Invest Radiol 2023 Apr 1;58(4):299-306.
    doi: 10.1097/RLI.0000000000000935pubmed: 36730906google scholar: lookup
  15. Isser S, Maurer A, Reischl G, Schaller M, Gonzalez-Menendez I, Quintanilla-Martinez L, Gawaz M, Pichler BJ, Beziere N. Radiolabeled GPVI-Fc for PET Imaging of Multiple Extracellular Matrix Fibers: A New Look into Pulmonary Fibrosis Progression. J Nucl Med 2023 Jun;64(6):940-945.
    doi: 10.2967/jnumed.122.264552pubmed: 36702555google scholar: lookup
  16. Gabryś HS, Gote-Schniering J, Brunner M, Bogowicz M, Blüthgen C, Frauenfelder T, Guckenberger M, Maurer B, Tanadini-Lang S. Transferability of radiomic signatures from experimental to human interstitial lung disease. Front Med (Lausanne) 2022;9:988927.
    doi: 10.3389/fmed.2022.988927pubmed: 36465941google scholar: lookup
  17. Ebrahimpour A, Ahir M, Wang M, Jegga AG, Bonnen MD, Eissa NT, Montesi SB, Raghu G, Ghebre YT. Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis. Sci Rep 2022 Nov 30;12(1):20668.
    doi: 10.1038/s41598-022-24985-xpubmed: 36450789google scholar: lookup
  18. Seyran M, Melanie S, Philip S, Amiq G, Fabian B. Allies or enemies? The effect of regulatory T cells and related T lymphocytes on the profibrotic environment in bleomycin-injured lung mouse models. Clin Exp Med 2023 Aug;23(4):1075-1088.
    doi: 10.1007/s10238-022-00945-7pubmed: 36403186google scholar: lookup
  19. Ruigrok MJR, Roest MAP, Frijlink HW, Olinga P, Hinrichs WLJ, Melgert BN. RANKL confers protection against cell death in precision-cut lung slices. Front Physiol 2022;13:1029697.
    doi: 10.3389/fphys.2022.1029697pubmed: 36388105google scholar: lookup
  20. Wu X, Xiao X, Chen X, Yang M, Hu Z, Shuai S, Fu Q, Yang H, Du Q. Effectiveness and mechanism of metformin in animal models of pulmonary fibrosis: A preclinical systematic review and meta-analysis. Front Pharmacol 2022;13:948101.
    doi: 10.3389/fphar.2022.948101pubmed: 36147352google scholar: lookup
  21. Egea-Zorrilla A, Vera L, Saez B, Pardo-Saganta A. Promises and Challenges of Cell-Based Therapies to Promote Lung Regeneration in Idiopathic Pulmonary Fibrosis. Cells 2022 Aug 20;11(16).
    doi: 10.3390/cells11162595pubmed: 36010671google scholar: lookup
  22. Pilling D, Sahlberg K, Karhadkar TR, Chen W, Gomer RH. The sialidase NEU3 promotes pulmonary fibrosis in mice. Respir Res 2022 Aug 23;23(1):215.
    doi: 10.1186/s12931-022-02146-ypubmed: 35999554google scholar: lookup
  23. Goertsen D, Goeden N, Flytzanis NC, Gradinaru V. Targeting the lung epithelium after intravenous delivery by directed evolution of underexplored sites on the AAV capsid. Mol Ther Methods Clin Dev 2022 Sep 8;26:331-342.
    doi: 10.1016/j.omtm.2022.07.010pubmed: 35990749google scholar: lookup
  24. Bosáková V, De Zuani M, Sládková L, Garlíková Z, Jose SS, Zelante T, Hortová Kohoutková M, Frič J. Lung Organoids-The Ultimate Tool to Dissect Pulmonary Diseases?. Front Cell Dev Biol 2022;10:899368.
    doi: 10.3389/fcell.2022.899368pubmed: 35912110google scholar: lookup
  25. Fukumoto J, Lin M, Banday MM, Patil SS, Krishnamurthy S, Breitzig M, Soundararajan R, Galam L, Narala VR, Johns C, Patel K, Dunning J, Lockey RF, Sharma NS, Kolliputi N. Aberrant Expression of ACO1 in Vasculatures Parallels Progression of Idiopathic Pulmonary Fibrosis. Front Pharmacol 2022;13:890380.
    doi: 10.3389/fphar.2022.890380pubmed: 35910393google scholar: lookup
  26. Desdiani D, Rengganis I, Djauzi S, Setiyono A, Sadikin M, Jusman SWA, Siregar NC, Suradi S, Eyanoer PC. Fibropreventive and Antifibrotic Effects of Uncaria gambir on Rats with Pulmonary Fibrosis. Evid Based Complement Alternat Med 2022;2022:6721958.
    doi: 10.1155/2022/6721958pubmed: 35795272google scholar: lookup
  27. Tanner L, Bergwik J, Single AB, Bhongir RKV, Erjefält JS, Egesten A. Zoledronic Acid Targeting of the Mevalonate Pathway Causes Reduced Cell Recruitment and Attenuates Pulmonary Fibrosis. Front Pharmacol 2022;13:899469.
    doi: 10.3389/fphar.2022.899469pubmed: 35721132google scholar: lookup
  28. Khalajzeyqami Z, Grandi A, Ferrini E, Ravanetti F, Leo L, Mambrini M, Giardino L, Villetti G, Stellari FF. Pivotal role of micro-CT technology in setting up an optimized lung fibrosis mouse model for drug screening. PLoS One 2022;17(6):e0270005.
    doi: 10.1371/journal.pone.0270005pubmed: 35704641google scholar: lookup
  29. Ciccimarra R, Bolognesi MM, Zoboli M, Cattoretti G, Stellari FF, Ravanetti F. The normal and fibrotic mouse lung classified by spatial proteomic analysis. Sci Rep 2022 May 24;12(1):8742.
    doi: 10.1038/s41598-022-12738-9pubmed: 35610327google scholar: lookup
  30. Nguyen J, Armstrong BS, Cowman S, Tomer Y, Veerabhadraiah SR, Beers MF, Venosa A. Immunophenotyping of Acute Inflammatory Exacerbations of Lung Injury Driven by Mutant Surfactant Protein-C: A Role for Inflammatory Eosinophils. Front Pharmacol 2022;13:875887.
    doi: 10.3389/fphar.2022.875887pubmed: 35571100google scholar: lookup
  31. Chen IC, Liu YC, Wu YH, Lo SH, Dai ZK, Hsu JH, Tseng YH. Evaluation of Proteasome Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis. Cells 2022 May 4;11(9).
    doi: 10.3390/cells11091543pubmed: 35563849google scholar: lookup
  32. Vazquez-Armendariz AI, Barroso MM, El Agha E, Herold S. 3D In Vitro Models: Novel Insights into Idiopathic Pulmonary Fibrosis Pathophysiology and Drug Screening. Cells 2022 May 2;11(9).
    doi: 10.3390/cells11091526pubmed: 35563831google scholar: lookup
  33. Bergantini L, d'Alessandro M, Gangi S, Cavallaro D, Campiani G, Butini S, Landi C, Bini L, Cameli P, Bargagli E. Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a New Protocol for Investigating the Mechanisms of Idiopathic Pulmonary Fibrosis. Cells 2022 Apr 24;11(9).
    doi: 10.3390/cells11091441pubmed: 35563747google scholar: lookup
  34. Yang XH, Wang FF, Chi XS, Wang XM, Cong JP, Hu Y, Zhang YZ. Disturbance of serum lipid metabolites and potential biomarkers in the Bleomycin model of pulmonary fibrosis in young mice. BMC Pulm Med 2022 May 4;22(1):176.
    doi: 10.1186/s12890-022-01972-6pubmed: 35509094google scholar: lookup
  35. Ma HY, N'Diaye EN, Caplazi P, Huang Z, Arlantico A, Jeet S, Wong A, Brightbill HD, Li Q, Wong WR, Sandoval W, Tam L, Newman R, Roose-Girma M, Ding N. BMP1 is not required for lung fibrosis in mice. Sci Rep 2022 Mar 31;12(1):5466.
    doi: 10.1038/s41598-022-09557-3pubmed: 35361882google scholar: lookup
  36. Westermann-Clark E, Soundararajan R, Fukumoto J, Patil SS, Stearns TM, Saji S, Czachor A, Hernandez-Cuervo H, Breitzig M, Krishnamurthy S, Lockey RF, Kolliputi N. Matrix Metalloproteinase 7 Expression and Apical Epithelial Defects in Atp8b1 Mutant Mouse Model of Pulmonary Fibrosis. Biomolecules 2022 Feb 9;12(2).
    doi: 10.3390/biom12020283pubmed: 35204783google scholar: lookup
  37. Saleh M, Fotook Kiaei SZ, Kavianpour M. Application of Wharton jelly-derived mesenchymal stem cells in patients with pulmonary fibrosis. Stem Cell Res Ther 2022 Feb 15;13(1):71.
    doi: 10.1186/s13287-022-02746-xpubmed: 35168663google scholar: lookup
  38. Yu QY, Tang XX. Irreversibility of Pulmonary Fibrosis. Aging Dis 2022 Feb;13(1):73-86.
    doi: 10.14336/AD.2021.0730pubmed: 35111363google scholar: lookup
  39. Soundararajan R, Varanasi SM, Patil SS, Srinivas S, Hernández-Cuervo H, Czachor A, Bulkhi A, Fukumoto J, Galam L, Lockey RF, Kolliputi N. Lung fibrosis is induced in ADAR2 overexpressing mice via HuR-induced CTGF signaling. FASEB J 2022 Feb;36(2):e22143.
    doi: 10.1096/fj.202101511Rpubmed: 34985777google scholar: lookup
  40. Suliman HB, Healy Z, Zobi F, Kraft BD, Welty-Wolf K, Smith J, Barkauskas C, Piantadosi CA. Nuclear respiratory factor-1 negatively regulates TGF-β1 and attenuates pulmonary fibrosis. iScience 2022 Jan 21;25(1):103535.
    doi: 10.1016/j.isci.2021.103535pubmed: 34977500google scholar: lookup
  41. Hou Y, Ding Y, Du D, Yu T, Zhou W, Cui Y, Nie H. Airway Basal Cells Mediate Hypoxia-Induced EMT by Increasing Ribosome Biogenesis. Front Pharmacol 2021;12:783946.
    doi: 10.3389/fphar.2021.783946pubmed: 34955855google scholar: lookup
  42. Weckerle J, Picart-Armada S, Klee S, Bretschneider T, Luippold AH, Rist W, Haslinger C, Schlüter H, Thomas MJ, Krawczyk B, Fernandez-Albert F, Kästle M, Veyel D. Mapping the metabolomic and lipidomic changes in the bleomycin model of pulmonary fibrosis in young and aged mice. Dis Model Mech 2022 Jan 1;15(1).
    doi: 10.1242/dmm.049105pubmed: 34845494google scholar: lookup
  43. Wang MY, Zhou TY, Zhang ZD, Liu HY, Zheng ZY, Xie HQ. Current therapeutic strategies for respiratory diseases using mesenchymal stem cells. MedComm (2020) 2021 Sep;2(3):351-380.
    doi: 10.1002/mco2.74pubmed: 34766151google scholar: lookup
  44. Miura Y, Lam M, Bourke JE, Kanazawa S. Bimodal fibrosis in a novel mouse model of bleomycin-induced usual interstitial pneumonia. Life Sci Alliance 2022 Jan;5(1).
    doi: 10.26508/lsa.202101059pubmed: 34728556google scholar: lookup
  45. Decaris ML, Schaub JR, Chen C, Cha J, Lee GG, Rexhepaj M, Ho SS, Rao V, Marlow MM, Kotak P, Budi EH, Hooi L, Wu J, Fridlib M, Martin SP, Huang S, Chen M, Muñoz M, Hom TF, Wolters PJ, Desai TJ, Rock F, Leftheris K, Morgans DJ, Lepist EI, Andre P, Lefebvre EA, Turner SM. Dual inhibition of α(v)β(6) and α(v)β(1) reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res 2021 Oct 19;22(1):265.
    doi: 10.1186/s12931-021-01863-0pubmed: 34666752google scholar: lookup
  46. Wang Y, Sang X, Shao R, Qin H, Chen X, Xue Z, Li L, Wang Y, Zhu Y, Chang Y, Gao X, Zhang B, Zhang H, Yang J. Xuanfei Baidu Decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway. J Ethnopharmacol 2022 Jan 30;283:114701.
    doi: 10.1016/j.jep.2021.114701pubmed: 34606948google scholar: lookup
  47. Toren D, Yanai H, Abu Taha R, Bunu G, Ursu E, Ziesche R, Tacutu R, Fraifeld VE. Systems biology analysis of lung fibrosis-related genes in the bleomycin mouse model. Sci Rep 2021 Sep 29;11(1):19269.
    doi: 10.1038/s41598-021-98674-6pubmed: 34588506google scholar: lookup
  48. Haine L, Bravais J, Yegen CH, Bernaudin JF, Marchant D, Planès C, Voituron N, Boncoeur E. Sleep Apnea in Idiopathic Pulmonary Fibrosis: A Molecular Investigation in an Experimental Model of Fibrosis and Intermittent Hypoxia. Life (Basel) 2021 Sep 15;11(9).
    doi: 10.3390/life11090973pubmed: 34575121google scholar: lookup
  49. Song S, Fu Z, Guan R, Zhao J, Yang P, Li Y, Yin H, Lai Y, Gong G, Zhao S, Yu J, Peng X, He Y, Luo Y, Zhong N, Su J. Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis. Eur Respir J 2022 May;59(5).
    doi: 10.1183/13993003.00864-2021pubmed: 34561295google scholar: lookup
  50. Huan C, Xu W, Liu Y, Ruan K, Shi Y, Cheng H, Zhang X, Ke Y, Zhou J. Gremlin2 Activates Fibroblasts to Promote Pulmonary Fibrosis Through the Bone Morphogenic Protein Pathway. Front Mol Biosci 2021;8:683267.
    doi: 10.3389/fmolb.2021.683267pubmed: 34422900google scholar: lookup
  51. Stecker IR, Freeman MS, Sitaraman S, Hall CS, Niedbalski PJ, Hendricks AJ, Martin EP, Weaver TE, Cleveland ZI. Preclinical MRI to Quantify Pulmonary Disease Severity and Trajectories in Poorly Characterized Mouse Models: A Pedagogical Example Using Data from Novel Transgenic Models of Lung Fibrosis. J Magn Reson Open 2021 Jun;6-7.
    doi: 10.1016/j.jmro.2021.100013pubmed: 34414381google scholar: lookup
  52. Chang J, Nie H, Ge X, Du J, Liu W, Li X, Sun Y, Wei X, Xun Z, Li YC. Vitamin D suppresses bleomycin-induced pulmonary fibrosis by targeting the local renin-angiotensin system in the lung. Sci Rep 2021 Aug 16;11(1):16525.
    doi: 10.1038/s41598-021-96152-7pubmed: 34400742google scholar: lookup
  53. Vasse GF, Van Os L, De Jager M, Jonker MR, Borghuis T, Van Den Toorn LT, Jellema P, White ES, Van Rijn P, Harmsen MC, Heijink IH, Melgert BN, Burgess JK. Adipose Stromal Cell-Secretome Counteracts Profibrotic Signals From IPF Lung Matrices. Front Pharmacol 2021;12:669037.
    doi: 10.3389/fphar.2021.669037pubmed: 34393771google scholar: lookup
  54. Ruan H, Luan J, Gao S, Li S, Jiang Q, Liu R, Liang Q, Zhang R, Zhang F, Li X, Zhou H, Yang C. Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway. Molecules 2021 Jul 26;26(15).
    doi: 10.3390/molecules26154491pubmed: 34361644google scholar: lookup
  55. Doni A, Mantovani A, Bottazzi B, Russo RC. PTX3 Regulation of Inflammation, Hemostatic Response, Tissue Repair, and Resolution of Fibrosis Favors a Role in Limiting Idiopathic Pulmonary Fibrosis. Front Immunol 2021;12:676702.
    doi: 10.3389/fimmu.2021.676702pubmed: 34276664google scholar: lookup
  56. Solopov P, Colunga Biancatelli RML, Dimitropoulou C, Catravas JD. Sex-Related Differences in Murine Models of Chemically Induced Pulmonary Fibrosis. Int J Mol Sci 2021 May 31;22(11).
    doi: 10.3390/ijms22115909pubmed: 34072833google scholar: lookup
  57. Chen T, Zhang Z, Weng D, Lu L, Wang X, Xing M, Qiu H, Zhao M, Shen L, Zhou Y, Chang J, Li HP. Ion therapy of pulmonary fibrosis by inhalation of ionic solution derived from silicate bioceramics. Bioact Mater 2021 Oct;6(10):3194-3206.
    doi: 10.1016/j.bioactmat.2021.02.013pubmed: 33778199google scholar: lookup
  58. Ruigrok MJR, Frijlink HW, Melgert BN, Olinga P, Hinrichs WLJ. Gene therapy strategies for idiopathic pulmonary fibrosis: recent advances, current challenges, and future directions. Mol Ther Methods Clin Dev 2021 Mar 12;20:483-496.
    doi: 10.1016/j.omtm.2021.01.003pubmed: 33614824google scholar: lookup
  59. Khan MM, Poeckel D, Halavatyi A, Zukowska-Kasprzyk J, Stein F, Vappiani J, Sevin DC, Tischer C, Zinn N, Eley JD, Gudmann NS, Muley T, Winter H, Fisher AJ, Nanthakumar CB, Bergamini G, Pepperkok R. An integrated multiomic and quantitative label-free microscopy-based approach to study pro-fibrotic signalling in ex vivo human precision-cut lung slices. Eur Respir J 2021 Jul;58(1).
    doi: 10.1183/13993003.00221-2020pubmed: 33361096google scholar: lookup
  60. Bordag N, Biasin V, Schnoegl D, Valzano F, Jandl K, Nagy BM, Sharma N, Wygrecka M, Kwapiszewska G, Marsh LM. Machine Learning Analysis of the Bleomycin Mouse Model Reveals the Compartmental and Temporal Inflammatory Pulmonary Fingerprint. iScience 2020 Dec 18;23(12):101819.
    doi: 10.1016/j.isci.2020.101819pubmed: 33319168google scholar: lookup
  61. Xue H, Li M. Protective effect of pterostilbene on sepsis-induced acute lung injury in a rat model via the JAK2/STAT3 pathway. Ann Transl Med 2020 Nov;8(21):1452.
    doi: 10.21037/atm-20-5814pubmed: 33313197google scholar: lookup
  62. Courtoy GE, Leclercq I, Froidure A, Schiano G, Morelle J, Devuyst O, Huaux F, Bouzin C. Digital Image Analysis of Picrosirius Red Staining: A Robust Method for Multi-Organ Fibrosis Quantification and Characterization. Biomolecules 2020 Nov 22;10(11).
    doi: 10.3390/biom10111585pubmed: 33266431google scholar: lookup
  63. Kalidhindi RSR, Ambhore NS, Sathish V. Cellular and Biochemical Analysis of Bronchoalveolar Lavage Fluid from Murine Lungs. Methods Mol Biol 2021;2223:201-215.
    doi: 10.1007/978-1-0716-1001-5_15pubmed: 33226597google scholar: lookup
  64. Lee J, Kim JH, Hong SH, Yang SR. Organoid Model in Idiopathic Pulmonary Fibrosis. Int J Stem Cells 2021 Feb 28;14(1):1-8.
    doi: 10.15283/ijsc20093pubmed: 33122472google scholar: lookup
  65. Chaudhary S, Natt B, Bime C, Knox KS, Glassberg MK. Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused. Front Med (Lausanne) 2020;7:539.
    doi: 10.3389/fmed.2020.00539pubmed: 33072773google scholar: lookup
  66. Lingampally A, Jones MR, Bagari S, Chen C, Rivetti S, Bellusci S. Use of the Reversible Myogenic to Lipogenic Transdifferentiation Switch for the Design of Pre-clinical Drug Screening in Idiopathic Pulmonary Fibrosis. Front Bioeng Biotechnol 2020;8:569865.
    doi: 10.3389/fbioe.2020.569865pubmed: 33042971google scholar: lookup
  67. Uray KS, Peng Z, Cattano D, Eltzschig HK, Doursout MF. Development of pulmonary fibrosis after heart failure induced by elevated left atrial pressure. Am J Transl Res 2020;12(8):4639-4647.
    pubmed: 32913537
  68. Chow MYT, Qiu Y, Lam JKW. Inhaled RNA Therapy: From Promise to Reality. Trends Pharmacol Sci 2020 Oct;41(10):715-729.
    doi: 10.1016/j.tips.2020.08.002pubmed: 32893004google scholar: lookup
  69. Varma R, Soleas JP, Waddell TK, Karoubi G, McGuigan AP. Current strategies and opportunities to manufacture cells for modeling human lungs. Adv Drug Deliv Rev 2020;161-162:90-109.
    doi: 10.1016/j.addr.2020.08.005pubmed: 32835746google scholar: lookup
  70. Miles T, Hoyne GF, Knight DA, Fear MW, Mutsaers SE, Prêle CM. The contribution of animal models to understanding the role of the immune system in human idiopathic pulmonary fibrosis. Clin Transl Immunology 2020;9(7):e1153.
    doi: 10.1002/cti2.1153pubmed: 32742653google scholar: lookup
  71. Caporarello N, Meridew JA, Aravamudhan A, Jones DL, Austin SA, Pham TX, Haak AJ, Moo Choi K, Tan Q, Haresi A, Huang SK, Katusic ZS, Tschumperlin DJ, Ligresti G. Vascular dysfunction in aged mice contributes to persistent lung fibrosis. Aging Cell 2020 Aug;19(8):e13196.
    doi: 10.1111/acel.13196pubmed: 32691484google scholar: lookup
  72. Zhang F, Ayaub EA, Wang B, Puchulu-Campanella E, Li YH, Hettiarachchi SU, Lindeman SD, Luo Q, Rout S, Srinivasarao M, Cox A, Tsoyi K, Nickerson-Nutter C, Rosas IO, Low PS. Reprogramming of profibrotic macrophages for treatment of bleomycin-induced pulmonary fibrosis. EMBO Mol Med 2020 Aug 7;12(8):e12034.
    doi: 10.15252/emmm.202012034pubmed: 32597014google scholar: lookup
  73. Bisserier M, Hadri L. Lung-targeted SERCA2a Gene Therapy: From Discovery to Therapeutic Application in Bleomycin-Induced Pulmonary Fibrosis. J Cell Immunol 2020;2(4):149-156.
    pubmed: 32587955
  74. Jiang J, Wang F, Luo A, Lin S, Feng X, Yan W, Shi Y, Zhang Q, Gu X, Cui G, Wang J, Wang L, Zhang Q, Tan W. Polyporus Polysaccharide Ameliorates Bleomycin-Induced Pulmonary Fibrosis by Suppressing Myofibroblast Differentiation via TGF-β/Smad2/3 Pathway. Front Pharmacol 2020;11:767.
    doi: 10.3389/fphar.2020.00767pubmed: 32528292google scholar: lookup
  75. Cores J, Dinh PC, Hensley T, Adler KB, Lobo LJ, Cheng K. A pre-investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis. Stem Cells Transl Med 2020 Jul;9(7):786-798.
    doi: 10.1002/sctm.19-0167pubmed: 32304182google scholar: lookup
  76. Leslie J, Millar BJ, Del Carpio Pons A, Burgoyne RA, Frost JD, Barksby BS, Luli S, Scott J, Simpson AJ, Gauldie J, Murray LA, Finch DK, Carruthers AM, Ferguson J, Sleeman MA, Rider D, Howarth R, Fox C, Oakley F, Fisher AJ, Mann DA, Borthwick LA. FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis. JCI Insight 2020 Feb 27;5(4).
    doi: 10.1172/jci.insight.125937pubmed: 32102985google scholar: lookup
  77. Ravanetti F, Ragionieri L, Ciccimarra R, Ruscitti F, Pompilio D, Gazza F, Villetti G, Cacchioli A, Stellari FF. Modeling pulmonary fibrosis through bleomycin delivered by osmotic minipump: a new histomorphometric method of evaluation. Am J Physiol Lung Cell Mol Physiol 2020 Feb 1;318(2):L376-L385.
    doi: 10.1152/ajplung.00311.2019pubmed: 31851533google scholar: lookup
  78. Vijayaraj P, Minasyan A, Durra A, Karumbayaram S, Mehrabi M, Aros CJ, Ahadome SD, Shia DW, Chung K, Sandlin JM, Darmawan KF, Bhatt KV, Manze CC, Paul MK, Wilkinson DC, Yan W, Clark AT, Rickabaugh TM, Wallace WD, Graeber TG, Damoiseaux R, Gomperts BN. Modeling Progressive Fibrosis with Pluripotent Stem Cells Identifies an Anti-fibrotic Small Molecule. Cell Rep 2019 Dec 10;29(11):3488-3505.e9.
    doi: 10.1016/j.celrep.2019.11.019pubmed: 31825831google scholar: lookup
  79. Zhou B, Schaefbauer KJ, Egan AM, Carmona Porquera EM, Limper AH, Zhang X. An ex vivo technique for quantifying mouse lung injury using ultrasound surface wave elastography. J Biomech 2020 Jan 2;98:109468.
    doi: 10.1016/j.jbiomech.2019.109468pubmed: 31708243google scholar: lookup
  80. Pan H, Deutsch GH, Wert SE. Comprehensive anatomic ontologies for lung development: A comparison of alveolar formation and maturation within mouse and human lung. J Biomed Semantics 2019 Oct 24;10(1):18.
    doi: 10.1186/s13326-019-0209-1pubmed: 31651362google scholar: lookup
  81. Heukels P, van Hulst JAC, van Nimwegen M, Boorsma CE, Melgert BN, von der Thusen JH, van den Blink B, Hoek RAS, Miedema JR, Neys SFH, Corneth OBJ, Hendriks RW, Wijsenbeek MS, Kool M. Enhanced Bruton's tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis. Respir Res 2019 Oct 24;20(1):232.
    doi: 10.1186/s12931-019-1195-7pubmed: 31651327google scholar: lookup
  82. Gad ES, Salama AAA, El-Shafie MF, Arafa HMM, Abdelsalam RM, Khattab M. The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats. Inflammation 2020 Feb;43(1):123-134.
    doi: 10.1007/s10753-019-01101-2pubmed: 31646446google scholar: lookup
  83. Zhou Z, Kandhare AD, Kandhare AA, Bodhankar SL. Hesperidin ameliorates bleomycin-induced experimental pulmonary fibrosis via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways. EXCLI J 2019;18:723-745.
    doi: 10.17179/excli2019-1094pubmed: 31611754google scholar: lookup
  84. Petukhov D, Richter-Dayan M, Fridlender Z, Breuer R, Wallach-Dayan SB. Increased Regeneration Following Stress-Induced Lung Injury in Bleomycin-Treated Chimeric Mice with CD44 Knockout Mesenchymal Cells. Cells 2019 Oct 7;8(10).
    doi: 10.3390/cells8101211pubmed: 31591327google scholar: lookup
  85. Li L, Li Q, Wei L, Wang Z, Ma W, Liu F, Shen Y, Zhang S, Zhang X, Li H, Qian Y. Dexamethasone combined with berberine is an effective therapy for bleomycin-induced pulmonary fibrosis in rats. Exp Ther Med 2019 Oct;18(4):2385-2392.
    doi: 10.3892/etm.2019.7861pubmed: 31555349google scholar: lookup
  86. Tanner L, Single AB. Animal Models Reflecting Chronic Obstructive Pulmonary Disease and Related Respiratory Disorders: Translating Pre-Clinical Data into Clinical Relevance. J Innate Immun 2020;12(3):203-225.
    doi: 10.1159/000502489pubmed: 31527372google scholar: lookup
  87. Park JK, Coffey NJ, Bodine SP, Zawatsky CN, Jay L, Gahl WA, Kunos G, Gochuico BR, Malicdan MCV, Cinar R. Bleomycin Induces Drug Efflux in Lungs. A Pitfall for Pharmacological Studies of Pulmonary Fibrosis. Am J Respir Cell Mol Biol 2020 Feb;62(2):178-190.
    doi: 10.1165/rcmb.2018-0147OCpubmed: 31419911google scholar: lookup
  88. Caporarello N, Meridew JA, Jones DL, Tan Q, Haak AJ, Choi KM, Manlove LJ, Prakash YS, Tschumperlin DJ, Ligresti G. PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state. Thorax 2019 Aug;74(8):749-760.
    doi: 10.1136/thoraxjnl-2019-213064pubmed: 31182654google scholar: lookup
  89. Zhang E, Yang Y, Zhang J, Ding G, Chen S, Peng C, Lavin MF, Yeo AJ, Du Z, Shao H. Efficacy of bone marrow mesenchymal stem cell transplantation in animal models of pulmonary fibrosis after exposure to bleomycin: A meta-analysis. Exp Ther Med 2019 Mar;17(3):2247-2255.
    doi: 10.3892/etm.2019.7205pubmed: 30867709google scholar: lookup
  90. Rydell-Törmänen K, Johnson JR. The Applicability of Mouse Models to the Study of Human Disease. Methods Mol Biol 2019;1940:3-22.
    doi: 10.1007/978-1-4939-9086-3_1pubmed: 30788814google scholar: lookup
  91. Katz MG, Fargnoli AS, Gubara SM, Fish K, Weber T, Bridges CR, Hajjar RJ, Ishikawa K. Targeted Gene Delivery through the Respiratory System: Rationale for Intratracheal Gene Transfer. J Cardiovasc Dev Dis 2019 Feb 15;6(1).
    doi: 10.3390/jcdd6010008pubmed: 30781363google scholar: lookup
  92. Geng Y, Liu X, Liang J, Habiel DM, Kulur V, Coelho AL, Deng N, Xie T, Wang Y, Liu N, Huang G, Kurkciyan A, Liu Z, Tang J, Hogaboam CM, Jiang D, Noble PW. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight 2019 Mar 21;4(6).
    doi: 10.1172/jci.insight.125326pubmed: 30763282google scholar: lookup
  93. Lindeman JH, Matsumura JS. Pharmacologic Management of Aneurysms. Circ Res 2019 Feb 15;124(4):631-646.
    doi: 10.1161/CIRCRESAHA.118.312439pubmed: 30763216google scholar: lookup
  94. Campa CC, Silva RL, Margaria JP, Pirali T, Mattos MS, Kraemer LR, Reis DC, Grosa G, Copperi F, Dalmarco EM, Lima-Júnior RCP, Aprile S, Sala V, Dal Bello F, Prado DS, Alves-Filho JC, Medana C, Cassali GD, Tron GC, Teixeira MM, Ciraolo E, Russo RC, Hirsch E. Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis. Nat Commun 2018 Dec 12;9(1):5232.
    doi: 10.1038/s41467-018-07698-6pubmed: 30542075google scholar: lookup
  95. Pilling D, Gomer RH. The Development of Serum Amyloid P as a Possible Therapeutic. Front Immunol 2018;9:2328.
    doi: 10.3389/fimmu.2018.02328pubmed: 30459752google scholar: lookup
  96. Kim KH, Lee S, Lee H, Shin D, Min D, Kim M, Ryu B, Kim HW, Bae H. A standardized herbal extract PM014 ameliorates pulmonary fibrosis by suppressing the TGF-β1 pathway. Sci Rep 2018 Nov 15;8(1):16860.
    doi: 10.1038/s41598-018-35320-8pubmed: 30443024google scholar: lookup
  97. Barbayianni I, Ninou I, Tzouvelekis A, Aidinis V. Bleomycin Revisited: A Direct Comparison of the Intratracheal Micro-Spraying and the Oropharyngeal Aspiration Routes of Bleomycin Administration in Mice. Front Med (Lausanne) 2018;5:269.
    doi: 10.3389/fmed.2018.00269pubmed: 30320115google scholar: lookup
  98. Zhang WZ, Butler JJ, Cloonan SM. Smoking-induced iron dysregulation in the lung. Free Radic Biol Med 2019 Mar;133:238-247.
    doi: 10.1016/j.freeradbiomed.2018.07.024pubmed: 30075191google scholar: lookup
  99. Tzouvelekis A, Toonkel R, Karampitsakos T, Medapalli K, Ninou I, Aidinis V, Bouros D, Glassberg MK. Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis. Front Med (Lausanne) 2018;5:142.
    doi: 10.3389/fmed.2018.00142pubmed: 29868594google scholar: lookup
  100. Arora A, Bhuria V, Hazari PP, Pathak U, Mathur S, Roy BG, Sandhir R, Soni R, Dwarakanath BS, Bhatt AN. Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice. Front Pharmacol 2018;9:394.
    doi: 10.3389/fphar.2018.00394pubmed: 29740320google scholar: lookup
  101. Mikamo M, Kitagawa K, Sakai S, Uchida C, Ohhata T, Nishimoto K, Niida H, Suzuki S, Nakayama KI, Inui N, Suda T, Kitagawa M. Inhibiting Skp2 E3 Ligase Suppresses Bleomycin-Induced Pulmonary Fibrosis. Int J Mol Sci 2018 Feb 6;19(2).
    doi: 10.3390/ijms19020474pubmed: 29415439google scholar: lookup
  102. Pulley JM, Jerome RN, Zaleski NM, Shirey-Rice JK, Pruijssers AJ, Lavieri RR, Chettiar SN, Naylor HM, Aronoff DM, Edwards DA, Niswender CM, Dugan LL, Crofford LJ, Bernard GR, Holroyd KJ. When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data. Assay Drug Dev Technol 2017 Dec;15(8):354-361.
    doi: 10.1089/adt.2017.821pubmed: 29193979google scholar: lookup
  103. Weissenböck V, Schlederer M, Bakiri L, Schaffenrath J, Wagner EF, Rösch F, Hacker M, Kenner L, Philippe C. FAPI Tracer en Vogue: Evaluating [(68)Ga]Ga-DATA(5m).SA.FAPi for Molecular Imaging of Pulmonary Fibrosis. Pharmaceuticals (Basel) 2025 Dec 23;19(1).
    doi: 10.3390/ph19010034pubmed: 41599636google scholar: lookup
  104. Zhou M, Brinson D, Lei C, Karoubi G. Recent Advancements in the Generation and Application of Therapeutic Cell Populations for Lung Epithelial Repair. J Tissue Eng Regen Med 2025;2025:8367426.
    doi: 10.1155/term/8367426pubmed: 41479466google scholar: lookup
  105. Wu S, Driver I, Luo M, Miyazaki H, Shambhu S, Popov D, Yang L, Wang J, Ma J, Guo J, Atha J, Tata A, Hoffman EA, Wang Y, Tata PR, Jensen MB, Engelhardt JF, Sontake V, Liu X. Ferret model of bleomycin-induced lung injury shares features of human idiopathic pulmonary fibrosis. NPJ Regen Med 2025 Nov 21;10(1):53.
    doi: 10.1038/s41536-025-00440-zpubmed: 41271777google scholar: lookup
  106. Soliveres E, Pierrot E, Fastrès A, Roels E, Clercx C, Bolen G. A High Number of Ring-Down Artefacts and an Irregular Pleural Surface Are More Commonly Observed in WHWTs Suffering from Idiopathic Pulmonary Fibrosis Compared to Control WHWTs. Animals (Basel) 2025 Oct 13;15(20).
    doi: 10.3390/ani15202964pubmed: 41153891google scholar: lookup
  107. Ham S, Jeong SH, Lee H, Nam YJ, Lee H, Choi JY, Lee YS, Park YH, Park SA, Kim W, Choi H, Kim H, Lee JH, Kim C. Enhancing Lesion Detection in Rat CT Images: A Deep Learning-Based Super-Resolution Study. Biomedicines 2025 Oct 3;13(10).
    doi: 10.3390/biomedicines13102421pubmed: 41153703google scholar: lookup
  108. Buchholzki M, Stasch LM, Budeus B, Ketheeswaranathan V, Sevindik ZF, Jendrossek V, Klein D. Senescent fibroblasts modulate the radiation response of neighboring epithelial cells. Cell Death Discov 2025 Oct 20;11(1):468.
    doi: 10.1038/s41420-025-02796-zpubmed: 41115895google scholar: lookup
  109. Yin Y, Jia N, Luo H, Feng X, He X, Huang J, Wang F. Protective effects and mechanism of resveratrol in animal models of pulmonary fibrosis: a preclinical systematic review and meta-analysis. Front Pharmacol 2025;16:1666698.
    doi: 10.3389/fphar.2025.1666698pubmed: 41089832google scholar: lookup
  110. Hasan MN, Chae Y, Lee SY, Kang YM. Establishment of a humanized mouse model of pulmonary fibrosis for advancing drug validation strategies. Sci Rep 2025 Oct 6;15(1):34748.
    doi: 10.1038/s41598-025-18370-7pubmed: 41053150google scholar: lookup
  111. Zhang S, Xue Y, Zhang X, Chen F, Li Y, Zhang W. Therapeutic effects and potential mechanisms of astragaloside IV on pulmonary fibrosis: a systematic review and meta-analysis of preclinical studies. Front Pharmacol 2025;16:1564290.
    doi: 10.3389/fphar.2025.1564290pubmed: 40822469google scholar: lookup
  112. Elgohary R, Abd Elwahab S, Salama A. Investigation into the protective effects of protocatechuic acid in bleomycin-induced pulmonary remodeling and fibrosis in rats: role of MMP-2/TIMP-1 and CTGF/NOX4 pathway. Naunyn Schmiedebergs Arch Pharmacol 2026 Jan;399(1):549-560.
    doi: 10.1007/s00210-025-04410-6pubmed: 40637744google scholar: lookup
  113. Parajuli N, Yao Y, Khalasawi N, Yin C, Zhang Q, Adrianto I, Hans A, Zhou L, Mi QS. MicroRNAs regulate alveolar macrophage homeostasis and its function in lung fibrosis. Front Immunol 2025;16:1598306.
    doi: 10.3389/fimmu.2025.1598306pubmed: 40625745google scholar: lookup
  114. Zheng Y, Schupp JC, Adams T, Clair G, Justet A, Ahangari F, Yan X, Hansen P, Carlon M, Cortesi E, Vermant M, Vos R, De Sadeleer LJ, Rosas IO, Pineda R, Sembrat J, Königshoff M, McDonough JE, Vanaudenaerde BM, Wuyts WA, Kaminski N, Ding J. A deep generative model for deciphering cellular dynamics and in silico drug discovery in complex diseases. Nat Biomed Eng 2025 Dec;9(12):2155-2180.
    doi: 10.1038/s41551-025-01423-7pubmed: 40542107google scholar: lookup
  115. Chen K, Zhang H, Yao Z, Tao S, Ma Q. Current advancements in the mechanisms and animal models of acute exacerbation of pulmonary fibrosis: a systematic review. Front Pharmacol 2025;16:1501085.
    doi: 10.3389/fphar.2025.1501085pubmed: 40520197google scholar: lookup
  116. Ye HL, Meng XQ, Li H, Sun X, Lin WZ, Zhou LJ, Zhang J, Hou C, Xu S, Chen BY, Qiu C, Li YL, Wang YL, Yan LF, Duan SZ. Periodontitis aggravates pulmonary fibrosis by Porphyromonas gingivalis-promoted infiltration of neutrophils and Th17 cells. Front Cell Infect Microbiol 2025;15:1595500.
    doi: 10.3389/fcimb.2025.1595500pubmed: 40496020google scholar: lookup
  117. Wu S, Drive I, Luo M, Miyazaki H, Shambhu S, Popov D, Yang L, Wang J, Ma J, Guo J, Atha J, Tata A, Hoffman EA, Wang Y, Tata PR, Jensen MB, Engelhardt JF, Sontake V, Liu X. Ferret model of bleomycin-induced lung injury shares features of human idiopathic pulmonary fibrosis. bioRxiv 2025 May 14;.
    doi: 10.1101/2025.05.08.652970pubmed: 40462941google scholar: lookup
  118. Ryszkiewicz P, Schlicker E, Malinowska B. Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?. Antioxidants (Basel) 2025 Mar 21;14(4).
    doi: 10.3390/antiox14040377pubmed: 40298665google scholar: lookup
  119. Krishnan A, Sreelatha HV, Arumugam S, Kasoju N. Human Wharton's Jelly Mesenchymal Stem Cells and their Extracellular Vesicles in the Management of Bleomycin-induced Lung Injury in Model Animals: A Comparative Preclinical Study Focused on Histomorphometric Analysis. Curr Stem Cell Res Ther 2025;20(11):1184-1197.
    doi: 10.2174/011574888X366742250417065341pubmed: 40289988google scholar: lookup
  120. Karsdal M, Cox TR, Parker AL, Willumsen N, Sand JMB, Jenkins G, Hansen HH, Oldenburger A, Geillinger-Kaestle KE, Larsen AT, Black D, Genovese F, Eckersley A, Heinz A, Nyström A, Holm Nielsen S, Bennink L, Johannsson L, Bay-Jensen AC, Orange DE, Friedman S, Røpke M, Fiore V, Schuppan D, Rieder F, Simona B, Borthwick L, Skarsfeldt M, Wennbo H, Thakker P, Stoffel R, Clarke GW, Kalluri R, Ruane D, Zannad F, Mortensen JH, Sinkeviciute D, Sundberg F, Coseno M, Thudium C, Croft AP, Khanna D, Cooreman M, Broermann A, Leeming DJ, Mobasheri A, Ricard-Blum S. Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics. J Clin Med 2025 Mar 10;14(6).
    doi: 10.3390/jcm14061856pubmed: 40142664google scholar: lookup
  121. Nagy L, Nagy G, Juhász T, Fillér C, Szűcs G, Szekanecz Z, Vereb G, Antal-Szalmás P, Szöőr Á. Comparative Evaluation of Bleomycin- and Collagen-V-Induced Models of Systemic Sclerosis: Insights into Fibrosis and Autoimmunity for Translational Research. Int J Mol Sci 2025 Mar 14;26(6).
    doi: 10.3390/ijms26062618pubmed: 40141262google scholar: lookup
  122. Liu H, Cui H, Liu G. The Intersection between Immune System and Idiopathic Pulmonary Fibrosis-A Concise Review. Fibrosis (Hong Kong) 2025;3(1).
    doi: 10.70322/fibrosis.2025.10004pubmed: 40124525google scholar: lookup
  123. Alghoull AE, Firdausi SR, Christina YI, Widyarti S, Rifa'i M, Djati MS. Evaluating the efficacy of ethanolic extract of Tapak Liman (Elephantopus scaber L.) leaf in inhibiting pulmonary fibrosis: Mechanisms through anti-fibrotic cytokine promotion. Open Vet J 2025 Jan;15(1):118-125.
    doi: 10.5455/OVJ.2025.v15.i1.11pubmed: 40092211google scholar: lookup
  124. Wu X, Xiao X, Su Y, Zhang Y, Li G, Wang F, Du Q, Yang H. Use quercetin for pulmonary fibrosis: a preclinical systematic review and meta-analysis. Inflammopharmacology 2025 Apr;33(4):1879-1897.
    doi: 10.1007/s10787-025-01678-1pubmed: 40038212google scholar: lookup
  125. Zhang X, Li S, Lason W, Greco M, Klenerman P, Hinks TSC. MAIT cells protect against sterile lung injury. Cell Rep 2025 Feb 25;44(2):115275.
    doi: 10.1016/j.celrep.2025.115275pubmed: 39918959google scholar: lookup
  126. Wang M, Sun Y, Zhao Y, Jiang X, Wang T, Xie J, Yu X, Guo S, Zhang Y, Chen X, Hong A. An FGF2-Derived Short Peptide Attenuates Bleomycin-Induced Pulmonary Fibrosis by Inhibiting Collagen Deposition and Epithelial-Mesenchymal Transition via the FGFR/MAPK Signaling Pathway. Int J Mol Sci 2025 Jan 9;26(2).
    doi: 10.3390/ijms26020517pubmed: 39859240google scholar: lookup
  127. Goto T, Sano A, Onishi S, Hada N, Kimata R, Matsuo S, Oyama S, Kato A, Mizuno H, Yamazaki M. Optimized digital workflow for pathologist-grade evaluation in bleomycin-induced pulmonary fibrosis mouse model. Sci Rep 2025 Jan 17;15(1):2331.
    doi: 10.1038/s41598-025-86544-4pubmed: 39833349google scholar: lookup
  128. Saghghaei F, Rassouli A, Sadeghi-Hashjin G, Sasani F, Koohi MK. Protective effects of Nigella sativa oil, thymoquinone and dexamethasone on bleomycin-induced lung fibrosis in rats. Vet Res Forum 2024;15(11):613-620.
    doi: 10.30466/vrf.2024.2024154.4196pubmed: 39807395google scholar: lookup
  129. Russo RC, Ryffel B. The Chemokine System as a Key Regulator of Pulmonary Fibrosis: Converging Pathways in Human Idiopathic Pulmonary Fibrosis (IPF) and the Bleomycin-Induced Lung Fibrosis Model in Mice. Cells 2024 Dec 12;13(24).
    doi: 10.3390/cells13242058pubmed: 39768150google scholar: lookup
  130. Ouji-Sageshima N, Hiyama A, Kumamoto M, Kitabatake M, Hara A, Furukawa R, Hontsu S, Kawaguchi T, Sawabata N, Muro S, Ito T. Adipose-Derived Mesenchymal Stem Cells (ADSCs) Have Anti-Fibrotic Effects on Lung Fibroblasts from Idiopathic Pulmonary Fibrosis (IPF) Patients. Cells 2024 Dec 12;13(24).
    doi: 10.3390/cells13242050pubmed: 39768142google scholar: lookup
  131. Kadam AH, Schnitzer JE. Highly Calibrated Relationship Between Bleomycin Concentrations and Facets of the Active Phase Fibrosis in Classical Mouse Bleomycin Model. Int J Mol Sci 2024 Nov 15;25(22).
    doi: 10.3390/ijms252212300pubmed: 39596365google scholar: lookup
  132. Wang S, Li J, Wu C, Lei Z, Wang T, Huang X, Zhang S, Liu Y, Bi X, Zheng F, Zhu X, Huang Z, Yi X. Single-Cell RNA Sequencing Reveals Monocyte-Derived Interstitial Macrophages with a Pro-Fibrotic Phenotype in Bleomycin-Induced Pulmonary Fibrosis. Int J Mol Sci 2024 Oct 30;25(21).
    doi: 10.3390/ijms252111669pubmed: 39519222google scholar: lookup
  133. Farooq H, Luehmann HP, Koenitzer JR, Heo GS, Sultan DH, Kulkarni DH, Gunsten SP, Sashti RM, Huang T, Keller AR, Lavine KJ, Atkinson JJ, Wingler LM, Liu Y, Brody SL. Molecular imaging in experimental pulmonary fibrosis reveals that nintedanib unexpectedly modulates CCR2 immune cell infiltration. EBioMedicine 2024 Dec;110:105431.
    doi: 10.1016/j.ebiom.2024.105431pubmed: 39515027google scholar: lookup
  134. Feng T, Cao J, Ma X, Wang X, Guo X, Yan N, Fan C, Bao S, Fan J. Animal models of chronic obstructive pulmonary disease: a systematic review. Front Med (Lausanne) 2024;11:1474870.
    doi: 10.3389/fmed.2024.1474870pubmed: 39512624google scholar: lookup
  135. Leitz DHW, Konietzke P, Wagner WL, Mertiny M, Benke C, Schneider T, Morty RE, Dullin C, Stiller W, Kauczor HU, Mall MA, Duerr J, Wielpütz MO. Longitudinal microcomputed tomography detects onset and progression of pulmonary fibrosis in conditional Nedd4-2 deficient mice. Am J Physiol Lung Cell Mol Physiol 2024 Dec 1;327(6):L917-L929.
    doi: 10.1152/ajplung.00280.2023pubmed: 39437758google scholar: lookup
  136. Petersen AG, Korntner SH, Bousamaki J, Oró D, Arraut AM, Pors SE, Salinas CG, Andersen MW, Madsen MR, Nie Y, Butts J, Roqueta-Rivera M, Simonsen U, Hansen HH, Feigh M. Reproducible lung protective effects of a TGFβR1/ALK5 inhibitor in a bleomycin-induced and spirometry-confirmed model of IPF in male mice. Physiol Rep 2024 Oct;12(19):e70077.
    doi: 10.14814/phy2.70077pubmed: 39394052google scholar: lookup
  137. Beikzadeh B, Khani M, Zarinehzadeh Y, Abedini Bakhshmand E, Sadeghizadeh M, Rabbani S, Soltani BM. Preventive and treatment efficiency of dendrosomal nano-curcumin against ISO-induced cardiac fibrosis in mouse model. PLoS One 2024;19(10):e0311817.
    doi: 10.1371/journal.pone.0311817pubmed: 39388499google scholar: lookup
  138. Göksu AY, Dirol H, Kocanci FG. Cromolyn sodium and masitinib combination inhibits fibroblast-myofibroblast transition and exerts additive cell-protective and antioxidant effects on a bleomycin-induced in vitro fibrosis model. Pharmacol Res Perspect 2024 Oct;12(5):e70018.
    doi: 10.1002/prp2.70018pubmed: 39360479google scholar: lookup
  139. Le NT, Dunleavy MW, Kumar RD, Zhou W, Bhatia SS, El-Hashash AH. Cellular therapies for idiopathic pulmonary fibrosis: current progress and future prospects. Am J Stem Cells 2024;13(4):191-211.
    doi: 10.62347/DAKS5508pubmed: 39308764google scholar: lookup
  140. Bell JA, Davies ER, Brereton CJ, Vukmirovic M, Roberts JJW, Lunn K, Wickens L, Conforti F, Ridley RA, Ceccato J, Sayer LN, Johnston DA, Vallejo AF, Alzetani A, Jogai S, Marshall BG, Fabre A, Richeldi L, Monk PD, Skipp P, Kaminski N, Offer E, Wang Y, Davies DE, Jones MG. Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2. Cell Rep Med 2024 Sep 17;5(9):101695.
    doi: 10.1016/j.xcrm.2024.101695pubmed: 39173635google scholar: lookup
  141. Liu Y, Tang P, Peng S, Zhong J, Xu Z, Zhong J, Su J, Zhong Y, Hu K. [(18)F]AlF-CBP imaging of type I collagen for non-invasive monitoring of pulmonary fibrosis in preclinical models. Eur J Nucl Med Mol Imaging 2024 Dec;52(1):22-35.
    doi: 10.1007/s00259-024-06888-3pubmed: 39172179google scholar: lookup
  142. Lauer D, Magnin CY, Kolly LR, Wang H, Brunner M, Chabria M, Cereghetti GM, Gabryś HS, Tanadini-Lang S, Uldry AC, Heller M, Verleden SE, Klein K, Sarbu AC, Funke-Chambour M, Ebner L, Distler O, Maurer B, Gote-Schniering J. Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosis. JCI Insight 2024 Jul 16;9(15).
    doi: 10.1172/jci.insight.181757pubmed: 39012714google scholar: lookup
  143. Finding EJT, Faulkner A, Nash L, Wheeler-Jones CPD. Equine Endothelial Cells Show Pro-Angiogenic Behaviours in Response to Fibroblast Growth Factor 2 but Not Vascular Endothelial Growth Factor A. Int J Mol Sci 2024 May 30;25(11).
    doi: 10.3390/ijms25116017pubmed: 38892205google scholar: lookup
  144. Hussein ZA, Abu-Raghif AR, Tahseen NJ, Rashed KA, Shaker NS, Fawzi HA. Vinpocetine alleviated alveolar epithelial cells injury in experimental pulmonary fibrosis by targeting PPAR-γ/NLRP3/NF-κB and TGF-β1/Smad2/3 pathways. Sci Rep 2024 May 15;14(1):11131.
    doi: 10.1038/s41598-024-61269-ypubmed: 38750140google scholar: lookup
  145. Grandi A, Ferrini E, Zoboli M, Buseghin D, Pennati F, Khalajzeyqami Z, Ciccimarra R, Villetti G, Stellari FF. A mouse model of progressive lung fibrosis with cutaneous involvement induced by a combination of oropharyngeal and osmotic minipump bleomycin delivery. Am J Physiol Lung Cell Mol Physiol 2024 Jun 1;326(6):L736-L753.
    doi: 10.1152/ajplung.00408.2023pubmed: 38651940google scholar: lookup
  146. Li Y, Jiang C, Zhu W, Lu S, Yu H, Meng L. Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis. Sci Prog 2024 Apr-Jun;107(2):368504241247402.
    doi: 10.1177/00368504241247402pubmed: 38651330google scholar: lookup
  147. Kadam AH, Schnitzer JE. Insights into Disease Progression of Translational Preclinical Rat Model of Interstitial Pulmonary Fibrosis through Endpoint Analysis. Cells 2024 Mar 15;13(6).
    doi: 10.3390/cells13060515pubmed: 38534359google scholar: lookup
  148. Fröhlich E. Animals in Respiratory Research. Int J Mol Sci 2024 Mar 1;25(5).
    doi: 10.3390/ijms25052903pubmed: 38474149google scholar: lookup
  149. Chen Y, Li Z, Ji G, Wang S, Mo C, Ding BS. Lung regeneration: diverse cell types and the therapeutic potential. MedComm (2020) 2024 Feb;5(2):e494.
    doi: 10.1002/mco2.494pubmed: 38405059google scholar: lookup
  150. Almuntashiri S, Alhumaid A, Zhu Y, Han Y, Dutta S, Khilji O, Zhang D, Wang X. TIMP-1 and its potential diagnostic and prognostic value in pulmonary diseases. Chin Med J Pulm Crit Care Med 2023 Jun;1(2):67-76.
    doi: 10.1016/j.pccm.2023.05.002pubmed: 38343891google scholar: lookup
  151. De Lorenzis E, Wasson CW, Del Galdo F. Alveolar epithelial-to-mesenchymal transition in scleroderma interstitial lung disease: Technical challenges, available evidence and therapeutic perspectives. J Scleroderma Relat Disord 2024 Feb;9(1):7-15.
    doi: 10.1177/23971983231181727pubmed: 38333528google scholar: lookup
  152. Sundar IK, Matson SM. Missing Nuts and Bolts: Translating Pulmonary Fibrosis from Preclinical Murine Models to Human Clinical Trials. Lung 2024 Apr;202(2):221-222.
    doi: 10.1007/s00408-024-00676-4pubmed: 38326503google scholar: lookup
  153. Escarrer-Garau G, Martín-Medina A, Truyols-Vives J, Gómez-Bellvert C, Elowsson L, Westergren-Thorsson G, Molina-Molina M, Mercader-Barceló J, Sala-Llinàs E. In Vivo and In Vitro Pro-Fibrotic Response of Lung-Resident Mesenchymal Stem Cells from Patients with Idiopathic Pulmonary Fibrosis. Cells 2024 Jan 16;13(2).
    doi: 10.3390/cells13020160pubmed: 38247851google scholar: lookup
  154. Kolanko E, Cargnoni A, Papait A, Silini AR, Czekaj P, Parolini O. The evolution of in vitro models of lung fibrosis: promising prospects for drug discovery. Eur Respir Rev 2024 Jan 31;33(171).
    doi: 10.1183/16000617.0127-2023pubmed: 38232990google scholar: lookup
  155. Zhang J, Guo Y, Mak M, Tao Z. Translational medicine for acute lung injury. J Transl Med 2024 Jan 5;22(1):25.
    doi: 10.1186/s12967-023-04828-7pubmed: 38183140google scholar: lookup
  156. Park SJ, Ryu HW, Kim JH, Hahn HJ, Jang HJ, Ko SK, Oh SR, Lee HJ. Daphnetin Alleviates Bleomycin-Induced Pulmonary Fibrosis through Inhibition of Epithelial-to-Mesenchymal Transition and IL-17A. Cells 2023 Dec 8;12(24).
    doi: 10.3390/cells12242795pubmed: 38132116google scholar: lookup
  157. Murgo A, Bignami F, Federico G, Villetti G, Civelli M, Sala A, Miglietta D. Harnessing the translational power of bleomycin model: new insights to guide drug discovery for idiopathic pulmonary fibrosis. Front Pharmacol 2023;14:1303646.
    doi: 10.3389/fphar.2023.1303646pubmed: 38099140google scholar: lookup
  158. Diwan R, Bhatt HN, Beaven E, Nurunnabi M. Emerging delivery approaches for targeted pulmonary fibrosis treatment. Adv Drug Deliv Rev 2024 Jan;204:115147.
    doi: 10.1016/j.addr.2023.115147pubmed: 38065244google scholar: lookup
  159. Khan A, Markus MA, Svetlove A, Hülsmann S, Alves F, Dullin C. Longitudinal x-ray based lung function measurement for monitoring Nintedanib treatment response in a mouse model of lung fibrosis. Sci Rep 2023 Oct 30;13(1):18637.
    doi: 10.1038/s41598-023-45305-xpubmed: 37903864google scholar: lookup
  160. Cala-Garcia JD, Medina-Rincon GJ, Sierra-Salas PA, Rojano J, Romero F. The Role of Mitochondrial Dysfunction in Idiopathic Pulmonary Fibrosis: New Perspectives for a Challenging Disease. Biology (Basel) 2023 Sep 14;12(9).
    doi: 10.3390/biology12091237pubmed: 37759636google scholar: lookup
  161. Galaris A, Fanidis D, Tsitoura E, Kanellopoulou P, Barbayianni I, Ntatsoulis K, Touloumi K, Gramenoudi S, Karampitsakos T, Tzouvelekis A, Antoniou K, Aidinis V. Increased lipocalin-2 expression in pulmonary inflammation and fibrosis. Front Med (Lausanne) 2023;10:1195501.
    doi: 10.3389/fmed.2023.1195501pubmed: 37746070google scholar: lookup
  162. Barbayianni I, Kanellopoulou P, Fanidis D, Nastos D, Ntouskou ED, Galaris A, Harokopos V, Hatzis P, Tsitoura E, Homer R, Kaminski N, Antoniou KM, Crestani B, Tzouvelekis A, Aidinis V. SRC and TKS5 mediated podosome formation in fibroblasts promotes extracellular matrix invasion and pulmonary fibrosis. Nat Commun 2023 Sep 21;14(1):5882.
    doi: 10.1038/s41467-023-41614-xpubmed: 37735172google scholar: lookup
  163. Bonatti M, Pitozzi V, Caruso P, Pontis S, Pittelli MG, Frati C, Mangiaracina C, Lagrasta CAM, Quaini F, Cantarella S, Ottonello S, Villetti G, Civelli M, Montanini B, Trevisani M. Time-course transcriptome analysis of a double challenge bleomycin-induced lung fibrosis rat model uncovers ECM homoeostasis-related translationally relevant genes. BMJ Open Respir Res 2023 Sep;10(1).
    doi: 10.1136/bmjresp-2022-001476pubmed: 37730279google scholar: lookup
  164. Vats A, Chaturvedi P. The Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis. Stem Cells Cloning 2023;16:43-59.
    doi: 10.2147/SCCAA.S419474pubmed: 37719787google scholar: lookup
  165. Kobayashi H, Tachi A, Hagita S. Time course of histopathology of bleomycin-induced pulmonary fibrosis using an intratracheal sprayer in mice. Exp Anim 2024 Feb 14;73(1):41-49.
    doi: 10.1538/expanim.23-0048pubmed: 37518267google scholar: lookup
  166. Ofori M, Danquah CA, Asante J, Ativui S, Doe P, Abdul-Nasir Taribabu A, Nugbemado IN, Mensah AN. Betulin and Crinum asiaticum L. bulbs extract attenuate pulmonary fibrosis by down regulating pro-fibrotic and pro-inflammatory cytokines in bleomycin-induced fibrosis mice model. Heliyon 2023 Jun;9(6):e16914.
    doi: 10.1016/j.heliyon.2023.e16914pubmed: 37346329google scholar: lookup
  167. Tanner L, Single AB, Bhongir RKV, Heusel M, Mohanty T, Karlsson CAQ, Pan L, Clausson CM, Bergwik J, Wang K, Andersson CK, Oommen RM, Erjefält JS, Malmström J, Wallner O, Boldogh I, Helleday T, Kalderén C, Egesten A. Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis in a murine lung fibrosis model. Nat Commun 2023 Feb 6;14(1):643.
    doi: 10.1038/s41467-023-36314-5pubmed: 36746968google scholar: lookup
  168. Williams DL. Animal models of scarring control. Eye (Lond) 2020 Feb;34(2):263-270.
    doi: 10.1038/s41433-019-0727-1pubmed: 31822860google scholar: lookup
Subscribe to our newsletter
Join 99,294 horse owners like you who receive our email updates on horse health and nutrition.